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About this report
The General Report of Activities is an annual publication 
providing a detailed progress report of the EMCDDA’s 
activities over a 12-month period. Published every 
spring, it catalogues the agency’s achievements in 
each area of its annual work programme. The report 
is a useful information source for all those seeking 
comprehensive information on the agency and its work.
About the EMCDDA
The European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA) is the central source and 
confirmed authority on drug-related issues in Europe. 
For over 20 years, it has been collecting, analysing and 
disseminating scientifically sound information on drugs 
and drug addiction and their consequences, providing 
its audiences with an evidence-based picture of the 
drug phenomenon at European level.
The EMCDDA’s publications are a prime source of 
information for a wide range of audiences including: 
policymakers and their advisors; professionals and 
researchers working in the drugs field; and, more 
broadly, the media and general public. Based in Lisbon, 
the EMCDDA is one of the decentralised agencies of 
the European Union.
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5  Foreword
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) hereby presents 
its 19th General Report of Activities to the European Parliament, the Council of the 
European Union, the European Commission, the Court of Auditors and the Member States.
The report provides an account of the EMCDDA’s activities and accomplishments in 2013, 
the first year of its three-year strategy and work programme for 2013–15.
During 2013, the EMCDDA continued to provide support to the European Union (EU) 
institutions and Member States in a range of activities in the drugs field. As an example, 
I would like to mention the Centre’s active participation in EU-funded projects, such as 
COPOLAD (Cooperation Programme between Latin America and the European Union on 
Drugs Policies) and CADAP (Central Asia Drug Action Programme). For the first time, 
representatives from Croatia participated in the Management Board at the July meeting, 
following the country’s accession to the European Union as the 28th Member State 
earlier that month.
The EMCDDA released, together with Europol, the first EU drug markets report: a strategic 
analysis, on 31 January in Brussels. The European Commissioner for Home Affairs, Cecilia 
Malmström, was joined at the press conference by EMCDDA Director Wolfgang Götz and 
Europol Director Rob Wainwright.
The EMCDDA presented its annual overview of the European drugs situation in a new, 
reshaped information package designed to be more timely, interactive and interlinked. 
The European Drug Report (EDR), which replaced the Annual report on the state of drugs 
problem in Europe, was launched on 28 May, nearly six months earlier than previously, 
and its key findings were announced at a press conference in the Centre’s headquarters 
on 28 May. The report was subsequently presented by the Director to the Committee on 
Civil Liberties, Justice and Home Affairs (LIBE) of the European Parliament on 30 May, as 
well as to a Justice and Home Affairs (JHA) Ministers meeting at the Council on 6 June, 
further to an invitation from the Irish Presidency.
I would like to express my gratitude to colleagues on the Management Board for their 
support to the objectives of the Centre. I would also like to sincerely thank the members 
of the Scientific Committee for their work and commitment during the past six years of 
their mandates, which came to an end in December last year.
My special thanks also go to Wolfgang Götz, Director, and the Centre’s staff, as well as the 
Heads of the Reitox national focal points and their staff, for their collaboration and 
professional commitment to the results achieved in 2013.
João Goulão 
Chairman of the EMCDDA Management Board

7 Introduction
Last year, the EMCDDA embarked on a new triennial strategy and work programme. The 
agency continued to monitor and report on the drugs situation in Europe while the ground 
was set for important new developments and improvements.
One major improvement was the launch of the European Drug Report package, the 
EMCDDA’s annual analysis of the drugs situation, in a redesigned format, to keep pace 
with both the rapidly-shifting drugs situation and the growing needs and changing 
expectations of our audiences.
The year was also marked by the release of another EMCDDA flagship publication, the first 
EU drug markets report: a strategic analysis. Produced together with our sister agency 
Europol, the report was launched in Brussels in January and during the course of the year 
it became a major reference source for policy analysis and decision-making at EU level. 
Together with two other EMCDDA publications, the report was nominated among the 
‘Notable Government Documents of 2012’ by the American Library Association. This 
brought further recognition for the scientific excellence of the Centre’s work.
Another priority for the year was to expand our networks of experts, which heighten the 
added value of our work. Over time, the EMCDDA has built an impressive range of 
networks in all areas related to the drugs phenomenon, including epidemiological key 
indicators, prevention, treatment and best practice, new drugs and trends, and laws. 
These networks were further consolidated in 2013, and new ones, such as the EMCDDA 
reference group on drug supply, were created.
In 2013, the agency and its partners in the Member States, Turkey and Norway, the Reitox 
network of national focal points, were faced with new challenges. While demands were 
higher than ever, resources were also tighter. The implementation of the EU Early Warning 
System on new drugs (EWS) was put under particular pressure, not only because of the 
continued increase in the number of new psychoactive substances notified, but because 
these substances raised more public health concerns than ever before. This meant that 
both the EMCDDA and our EWS partners needed to respond quickly with analyses for the 
European Commission and the Council, in order to support sound policy decisions.
At the same time, despite the obvious need for more resources to cope with critical 
developments in the European drugs situation, the EMCDDA was confronted with a 
decrease in its EU subsidy: a first since its creation 20 years ago. The reduction of over 
5 % in 2014 funds will have consequences on our co-financing of the national focal points, 
thus creating major challenges for reporting at country level. While the agency worked 
with the focal points to mitigate the impact of the budget decrease already experienced in 
2013, the situation will probably become critical during the course of 2014.
On a more positive note, on 30 October the EMCDDA celebrated 20 years since its 
founding Regulation came into effect. At the end of this particularly rich and meaningful 
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year, I would like to express my gratitude, once again, to the Management Board, the 
Scientific Committee, the Reitox national focal points and all our partners who made 
valuable contributions to our activities during the year. My thanks go also to my staff: as a 
team they made impressive achievements in 2013. I invite you to read about the 
highlights in our report.
Wolfgang Götz 
Director
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This report presents the implementation of the activities in the EMCDDA’s work 
programme for 2013, the first year of the agency’s triennial strategy for 2013–15.
The year 2013 was a special milestone for the Centre. On 30 October, the EMCDDA 
celebrated two decades since its founding Regulation, Council Regulation (EEC) No 
302/93, came into effect. Over the years, the agency has established strong mechanisms in 
Europe to carry out regular and sustained monitoring of developments in the drugs field, 
along with rapid responses to new trends and substances. A central challenge for the 
EMCDDA today is to continue to deliver high-quality analyses on established topics while 
extending its work in less developed but strategically important areas, with fewer resources.
The work of the agency is built on the core tasks of collecting, managing and analysing the 
data provided by the Reitox national focal points (NFPs) in the 30 countries reporting to 
the EMCDDA: the 28 Member States, Turkey and Norway. The findings gathered through 
this impressive collective effort form the basis for many outputs during the year.
In 2013, the EMCDDA presented its annual overview of the European drugs situation in a 
reshaped information package designed to be more timely, interactive and interlinked. 
Our flagship product, the European Drug Report (EDR), replaced the Annual report on 
the state of drugs problem in Europe. One of the EDR’s main improvements was 
timeliness, with the product being launched nearly six months earlier in the year than the 
previous report. Content and presentation were also improved. The 2013 package was 
designed as a set of integrated elements, giving full access to the data and analyses 
prepared, including: the Trends and developments report — a top-level overview of the 
drugs phenomenon in Europe; a new series of online analyses (Perspectives on drugs 
— PODs) providing deeper insight into selected issues; national data in Country 
overviews; the Statistical bulletin; and Health and social responses profiles.
The full EDR package was launched to the media on 28 May at a press conference at 
the EMCDDA, which opened with a video message from Commissioner Malmström. 
Furthermore, EMCDDA staff attended national launches organised in nine EU Member 
States.
At the heart of the EMCDDA’s work is the epidemiological monitoring of drug use 
prevalence and patterns, as well as health and social consequences. In 2013, we 
reinforced the foundations of our work in this area.
A cross-cutting priority for 2013 was to enhance the EMCDDA’s expert networks of 
excellence. Along with the NFPs, these feed into the extensive information and knowledge 
base that the agency has built over the years. The 2013–15 work programme makes 
maintaining and developing these networks a key concern. In 2013, we therefore 
overhauled the way in which large scientific meetings were organised, for example by 
CHAPTER 1
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holding a week-long event on ‘Measuring, understanding and responding to drug 
problems in Europe’, prompting meetings that were more productive.
In the area of demand reduction responses, 2013 was a very productive year, with seven 
new outputs, five expert meetings and three training events to enhance country capacity 
in monitoring drug responses across Europe and beyond. Publications included an 
Insights on Models of addiction, three papers on prevention and two PODs (on hepatitis C 
and on media campaigns), along with the online Health and social responses profiles, 
launched as part of the EDR package.
In 2013, the EMCDDA also gained ground in the implementation of its treatment strategy, 
published in April. This new tool was endorsed by the Heads of national focal points (HFP) 
and will be integrated into the 2014 data collection exercise.
Significant advances were also made in the area of best practice, including several 
scientific articles and online analyses, along with the development of the Best practice 
portal. Major training initiatives also helped disseminate knowledge on this topic.
The development of key indicators in the areas of drug markets, drug-related crime and 
drug supply reduction was a key task in 2013. Priority was given to developing two 
sub-indicators (drug seizures and drug production facilities). Central to scaling up work in 
this area is network development. In 2013, the reference group on drug supply was set up 
and met for the first time to discuss, among other things, its working arrangements, 
networking between members and the major challenges it faces.
A major event in 2013 was the launch of the first EU drug markets report: a strategic 
analysis, produced jointly with Europol. The event took place on 31 January, in Brussels, in 
a press conference held by Commissioner Malmström, EMCDDA Director Wolfgang Götz 
and Europol Director Rob Wainwright. An essential reference tool for law enforcement 
professionals, policymakers, the academic community and the general public, the report 
combines Europol’s strategic and operational understanding of trends and developments 
in organised crime with the EMCDDA’s ongoing monitoring and analysis of the drugs 
phenomenon.
As in previous years, the EMCDDA ensured the implementation of the EU Early Warning 
System on new drugs (EWS), together with Europol and its EWS partners in the Member 
States, the Reitox network. It was a particularly demanding year, as the number of new 
psychoactive substances (NPS) arriving on the market continued the upward trend 
started in previous years (81 NPS formally notified, compared with 73 in 2012). In four 
cases (methoxetamine, AH-7921, 25I-NBOMe and MDPV) data collection exercises were 
launched and EMCDDA–Europol Joint Reports were prepared and sent to the EC, the 
Council and the European Medicines Agency (EMA).
A risk assessment for 5-(2-aminopropyl)indole (5-IT) was successfully conducted by the 
Scientific Committee in April, as requested by the Council.
The 13th annual meeting of the Reitox EWS network took place in June. The event was 
organised in conjunction with the Europol second law enforcement meeting on NPS and 
followed by the third international multidisciplinary forum on new drugs, which attracted 
130 participants from around the world.
Monitoring new developments was also an important field of work in 2013. The EMCDDA 
launched a trendspotter study on methamphetamine in Europe, which culminated in an 
expert meeting in September. The study aimed to increase the overall understanding of 
Chapter 1 I Executive summary
15
methamphetamine trends in Europe, with a specific focus on production and trafficking 
issues, prevalence and patterns of use, health and social harms, and responses.
Another recent trend is the monitoring of drug residues in wastewater. The conference 
‘Testing the waters: first international multidisciplinary conference on detecting illicit 
drugs in wastewater’ was co-organised by the EMCDDA and the SEWPROF project in 
May. This event brought together 90 experts from 20 countries.
The EMCDDA launched several short reports during the year, including EMCDDA Papers 
on drug supply reduction and internal security policies in the EU, drug policy advocacy 
organisations in Europe, and a Drug policy profile on Ireland.
The 14th Meeting of the Legal Correspondents of the European Legal Database on Drugs 
(ELDD) was organised in October. The meeting brought together representatives from the 
30 EMCDDA reporting countries to exchange information on national and EU legal 
updates, including national laws controlling new drugs. The meeting took on a broader 
policy agenda this year, covering legislative and strategic developments, as well as public 
expenditure.
In the area of scientific coordination, top priorities in 2013 were to ensure the 
development, quality and coherence of the agency’s information collection and reporting 
system, to improve internal coordination and to enhance transversal work.
Increasing the coherence of our reporting system is one of the main commitments in the 
2013–15 work programme, following on from work started in 2011 (systemic review of 
tools). This includes the revision of the national reporting system, in close coordination 
with the NFPs. The revision will respond to the diminishing resources available at country 
level and reduced human and financial resources within the EMCDDA. This issue became 
critical in 2013, following the unexpected cut in the agency’s subsidy for 2014. One of the 
consequences of this drop of around 5 % will be less co-financing for the Reitox NFPs. The 
EMCDDA therefore worked with the focal points to address this issue.
Another core component of the Centre’s work is to develop a quality assurance framework 
for processes and statistical procedures. An EMCDDA cross-unit project (CUP) was set 
up in 2013, to develop a model for total data quality assurance management.
Disseminating scientific knowledge is a key task for the EMCDDA. This can be achieved 
through partnership with academic initiatives, as illustrated by the summer school 
project. Following the partnership launched in 2012 between the Instituto Superior das 
Ciências do Trabalho e da Empresa — Instituto Universitário de Lisboa (ISCTE–IUL) and 
the EMCDDA, the second edition of the summer school on ‘Drugs in Europe: supply, 
demand and public policies’ took place in 2013, with 28 students attending (25 from 11 
EU Member States and three from third countries).
As further recognition of the scientific excellence of the Centre´s work, three EMCDDA 
publications were nominated among the ‘Notable Government Documents of 2012’ by 
the American Library Association. The publications are the EU drug markets report: a 
strategic analysis (2013), Cannabis production and markets in Europe (Insights series, 
2012) and New heroin-assisted treatment: recent evidence and current practices of 
supervised injectable heroin treatment in Europe and beyond (Insights series, 2012).
The third EMCDDA Scientific paper award ceremony was organised as a fringe event at 
the Scientific Committee meeting in November. Inaugurated in 2011, the prize celebrates 
scientific writing and distinguishes high-quality research in the field of illicit drugs. The 
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2013 edition chose four winners, based in Germany, Austria and Norway and at the 
EMCDDA.
In 2013, the EMCDDA continued to support drug policy dialogue at EU level by providing 
expertise and technical information to the European Parliament (EP), the Council of the 
EU and the European Commission (EC).
Regarding collaboration with the EP, the Director presented the drug markets report and 
the EDR to the LIBE Committee in Brussels. Three members of the LIBE Committee also 
came to visit the EMCDDA in July. Moreover, EMCDDA staff provided technical input and 
attended several meetings with representatives of the EP in Brussels, on a range of 
topics.
In terms of cooperation with the Council of the EU, a key event was the Director’s 
presentation of the EDR to the Council of JHA Ministers on 6 June in Luxembourg.
Furthermore, the EMCDDA participated in the meetings of the Horizontal Drugs Group 
(HDG) held under the Irish and Lithuanian Presidencies, as well as various country 
dialogues and other relevant events.
The Centre also provided support for the preparation of the EU drugs action plan 2013–
16, adopted by the Council in June, and the EU policy cycle for organised and serious 
international crime 2013–17 within the Council’s Standing Committee on Operational 
Cooperation on Internal Security (COSI). In 2013, the agency fulfilled tasks under the 
operational action plan (OAP) for 2012–13, namely in the field of synthetic drugs, and 
helped define the priorities for the next policy cycle. Furthermore, the EMCDDA provided 
input to the drafting of the Council Conclusions on improving the monitoring of drug 
supply in the EU, adopted at the Economic and Financial Affairs Council meeting of 15 
November, in Brussels.
Throughout the year, the EMCDDA gave technical input to the EC on a range of issues, 
including: the new legal framework on NPS; policy dialogues between Directorate-
General (DG) Home Affairs and Member States (key national priorities on drugs); follow-
up of the project on Minimum Quality Standards in Drug Demand Reduction (EQUS); the 
updated EU action plan on HIV/AIDS; the evaluation of CADAP 5; and the EU–Central Asia 
political dialogue adopting the new EU–Central Asia Action Plan.
Collaboration was further strengthened with EU agencies, in particular with Europol, the 
European Police College (CEPOL), Eurojust, the European Medicines Agency (EMA) and 
the European Centre for Disease Prevention and Control (ECDC), while synergies were 
pursued with the European Maritime Safety Agency (EMSA) and the Fundamental Rights 
Agency (FRA). Cooperation with international organisations was also enhanced in 2013, 
in particular with the United Nations Office on Drugs and Crime (UNODC), the World 
Health Organization (WHO), the Council of Europe Pompidou Group and the Inter-
American Drug Abuse Control Commission from the Organisation of American States 
(CICAD–OAS).
Cooperation with candidate and potential candidate countries continued within the 
framework of the Instrument for Pre-Accession (IPA) programme technical assistance 
project started in 2012. An external evaluation of the project carried out in 2013 showed 
excellent results. The project received top marks (‘very good’) for four out of the six 
criteria monitored (relevance, quality of design, efficiency, impact). The two remaining 
criteria were graded as ‘good’. Capacity-building activities contributed to these 
outstanding results: 65 experts from IPA beneficiary countries attended the Reitox 
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Academies organised by the Centre and other key events, such as the Reitox week and 
expert meetings.
In 2013, the EMCDDA was awarded funding of EUR 450 000 for a two-year technical 
assistance project in European Neighbourhood Policy (ENP) countries. The project, called 
‘Towards a gradual improvement of ENP partner countries capacity to monitor and to 
meet drug-related challenges’ aims to strengthen the capacity of selected ENP partner 
countries (Armenia, Azerbaijan, Georgia, Israel, Moldova, Morocco and Ukraine) to react to 
new challenges and developments in the drugs situation in their respective countries. 
Implementation will start in 2014.
Communication is core to the EMCDDA’s mission to provide robust information on the 
drugs situation in Europe. Activities in 2013 were guided by the integrated 
communication strategy adopted by the Management Board in 2012, which makes 
communication activities an integral part of the agency’s scientific and technical activity, 
rather than an isolated function at project end.
The Centre’s key outputs to its audiences in 2013 included 41 online and printed 
publications complemented by additional online tools and web-based resources. All 
products were disseminated via the EMCDDA’s website and social media channels, along 
with news releases to mark the launch of key products. In addition, 34 scientific articles 
were published over the same period.
Furthermore, in 2013 EMCDDA staff participated in 277 international conferences, 
technical and scientific meetings (a full list of these events is presented in Annex 4 of this 
report, available at emcdda.europa.eu/publications/gra/2013/annex4.
The mandate of the EMCDDA’s Scientific Committee members came to an end in 
December 2013. A call for expressions of interest for new members was therefore 
launched in January and the Management Board appointed the new Scientific Committee 
members, along with a reserve list, during its December meeting.
The EMCDDA successfully implemented most of the activities contained in its work 
programme in 2013, achieving impressive results (for details, see Annex 5 of this report, 
available at emcdda.europa.eu/publications/gra/2013/annex5.
However, although the results were impressive, the period was also challenging as the 
impending cut in the Centre’s subsidy for 2014 already had repercussions. The Director 
and his staff strove to develop a realistic plan of action to immediately mitigate the impact 
of these restrictions, including a set of measures to rationalise the use of human, financial 
and material resources. Consequently, the 2014 work programme was prepared in a 
manner that sets clear priority levels for activities, according to the funds available.
As already mentioned, one of the consequences of the decrease in EU subsidy will be a 
cut in the EMCDDA’s co-financing of the Reitox NFPs. In view of this difficult reality, the 
NFPs welcomed the proposal for a revised Reitox national reporting system, which should 
allow both the Centre and the NFPs to better address the information needs of European 
and national stakeholders while rationalising resources.
General Report of Activities 2013
18
In terms of administration, the main priorities focused on enhancing efficiency, further 
developing sound management of available resources and providing service-oriented 
administrative support to the EMCDDA’s operations. In 2013, the EMCDDA showed 
outstandingly efficient management of its budget, by committing 99.74 % of funds by the 
end of the year and making 97.71 % of payments. Such success was possible only 
because of the efforts of all the staff involved across all core business and support areas.
2
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CHAPTER 2
Core business: monitoring 
and reporting on the drugs 
problem in Europe
I Data collection, analysis and quality assurance (Main area 1)
Data collection tasks are central to the EMCDDA’s mission. The purpose of the data 
collection is the aggregation and manipulation of data into tables, graphs and appropriate 
analyses for a range of both internal and external stakeholders. Internally the data are 
used to support reasoned descriptions of the drugs situation in the region, presented 
through the EMCDDA’s annual report on the drugs situation in Europe and other 
publications. Externally, policymakers, researchers, the European civil service and the 
general public have access to reliable and valid data on the drugs situation in each of the 
28 Member States, Norway and Turkey through the EMCDDA’s publications and the online 
Statistical bulletin.
The Centre’s data collection and analyses underwent major developments in 2013. Main 
areas for change included the new annual reporting package, the proposed modifications 
to the Statistical bulletin, the movement towards a statistical quality framework and the 
revision of the national reporting system.
I Main highlights and achievements from the area
In 2013, the EMCDDA presented its annual update on the European drugs situation in a 
reshaped information package designed to be more timely, interactive and interlinked. The 
EDR (4) replaced the Annual report on the state of drugs problem in Europe, which used to 
be launched every year around 15 November.
One of the most important features of the EDR package was its timeliness. It was 
launched nearly six months earlier in the year than the previous report. In order to meet 
this shorter deadline, the production process was completely redefined, including a new 
planning for the data collection and analysis component, which is the very basis of the 
EDR package.
Meeting this very ambitious production cycle was a major challenge in 2013, involving a 
significantly shorter timeline for data validation and analysis. This put a strain on both 
internal resources and the NFPs which provide the data.
(4) Available at emcdda.europa.eu/edr2013
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The European Drug Report presents the EMCDDA’s yearly 
overview of the drugs phenomenon. It is an essential 
reference point for policymakers, specialists and 
practitioners in the drugs field, or indeed anyone seeking 
the latest findings on drugs in Europe.
The 2013 package was designed as a set of integrated 
elements: the Trends and developments report, a 
top-level overview of the drug phenomenon in Europe, 
covering drug supply, use and public health problems, as 
well as drug policy and responses; web analyses 
providing special insight into key issues, called 
Perspectives on drugs (PODs); national data in Country 
overviews; the Statistical bulletin; and the Health and 
social responses profiles (see Main area 3).
The full EDR package for 2013 was launched to the media 
on 28 May at a press conference at the EMCDDA, which opened with a video message from 
Commissioner Cecilia Malmström (see more details in Main area 9).
Furthermore, the EMCDDA participated in national launches organised in nine EU Member 
States (Belgium, Bulgaria, Italy, Cyprus, Latvia, Portugal, Romania, Slovenia and Slovakia).
Furthermore, a revision of the structure of the Statistical bulletin started in 2013. The 
bulletin (5) is one of the main components of the EDR package, providing access to the 
data the EMCDDA uses for reporting on the drugs situation. The revision of its structure 
complements the emphasis on web products, to improve documentation of analyses and 
user-friendliness. Some early results of this revision were already visible in 2013, while full 
outcomes will be in place in 2015.
Another component of the EDR package is the Country overviews (6), containing a 
structured synopsis of the trends and characteristics of national drug problems for each 
of the 30 countries reporting to the EMCDDA. Each report contains a summary of the 
national drugs situation, key statistics at a glance and a barometer showing the drug use 
prevalence position of the country concerned in relation to the others.
During the year, work also started to prepare the 2014 EDR package. Revised data 
collection tools were made available to the NFPs on surveys of targeted groups, three key 
indicators (treatment demand indicator — TDI; problem drug use — PDU; and drug-
related infectious diseases — DRID) and behavioural data.
Furthermore, as part of its contribution to the development of a European methodological 
framework for monitoring drug use and responses in prisons, the Centre prepared a 
proposal for a common European questionnaire on drug use among prisoners (EQDP), 
based on the assessment of 45 questionnaires from 23 European countries. The 
questionnaire was discussed and agreed with a group of experts at a meeting held in 
May. The final outputs will be published in 2014.
Another commitment for this area in 2013–15 is to improve the performance of the 
reporting system, based on the results of the systemic review of tools launched in 2011 
(see Main area 7). This involves revising the national reporting system, which is vital in 
view of the reduced budget available and the resource constraints experienced by the 
countries reporting to the EMCDDA. There is now a clear and urgent need to rationalise 
investments at both EMCDDA and national data provider levels and efforts progressed in 
(5) Available at emcdda.europa.eu/stats13
(6) Available at emcdda.europa.eu/publications/country-overviews
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2013, in close consultation with the NFPs (for details, see Main area 10 — Reitox 
network).
Improving the performance of the reporting system involves strengthening the coherence 
of the reporting package, by introducing a more robust quality assurance framework for 
statistics. A cross-unit project on quality assurance (QA CUP) was set up in 2013 to 
develop a model for total data quality assurance management. In 2013, this CUP defined 
a set of principles for a statistical quality framework which the agency plans to adopt by 
the end of 2015.
As in every year, 30 quality reports were sent to the NFPs in May, providing feedback on 
the national reports submitted to the EMCDDA.
I  Monitoring and understanding drug use and problems: key indicators and epidemiology (Main area 2)
The epidemiological monitoring of drug use prevalence and patterns, as well as health 
and social consequences, lies at the heart of the EMCDDA’s work. This helps to paint an 
accurate picture of the drugs situation, which in turn leads to potential solutions and an 
evaluation of their efficiency. Epidemiological indicators (7) provide the long-term, 
standardised time series analysis that represents the main added value of the European 
monitoring system. We have developed standard methodologies to allow Member States 
to collect information in a sound and comparable way.
By the end of 2015, the Centre will be in a position to provide an improved overview of the 
European drugs situation, based on a more insightful analysis of epidemiological 
information combined with enhanced online resources. Work started on this in 2013.
I Main highlights and achievements from the area
Methodological development
In line with the three-year work programme, efforts in 2013 focused mainly on analysis 
and network development, in order to set solid foundations for the area. This included the 
preparation of new guidelines for online surveys, on cannabis disorders estimates and on 
the revised PDU indicator (2014 releases).
Furthermore, for the general population survey (GPS), a new European Model 
Questionnaire (EMQ) module on NPS was developed, based on input from an expert 
meeting.
In addition, the new DRID Toolkit (8) was published online in November for professionals 
working in the field.
(7)  The five indicators are general population surveys (GPS); treatment demand indicator (TDI); problem drug use 
(PDU); drug-related death (DRD); and drug-related infectious diseases (DRID).
(8) Available at emcdda.europa.en/activities/drid
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In line with the new EMCDDA treatment strategy (see Main area 3), the TDI prevalence 
module was finalised with input from an expert meeting. It will be piloted in 2014 with a 
number of volunteer NFPs.
Support to the European School Survey Project on Alcohol and Other Drugs 
(ESPAD)
The year 2013 was important for our collaboration with ESPAD. Following the 
Management Board’s support for a closer working relationship between the agency and 
ESPAD in 2011, the EMCDDA became the host of the ESPAD coordination in January 
2013 and during the ESPAD project meeting in October the EMCDDA was given a more 
formal role in ESPAD’s decision-making bodies.
Furthermore, the EMCDDA hosted the meeting of the ESPAD questionnaire group in 
February.
A joint analysis on polydrug use patterns with the most recent ESPAD data was 
conducted in 2013. It includes comparisons with available data from general population 
adult surveys and will be published in early 2014.
Capacity building for EU and non-EU countries
Improving in-country capacity in relation to implementation and reporting on the key 
epidemiological indicators is a vital task. As in previous years, the EMCDDA provided 
support to the focal points in 2013. This included regular contacts and exchanges, and 
specific training activities via the Reitox Academies programme (for more details, see 
Main area 10 — Reitox network).
Two Reitox Academies were organised during the year: a training course on Fonte XML, 
including a presentation of the new template for TDI (May) for representatives from 10 
NFPs; and a Reitox Regional Academy for Baltic countries, focusing on monitoring trends 
and responses to drug-related infectious diseases in people who inject drugs (November). 
This involved 16 participants and NFP experts from four Member States.
Furthermore, a workshop on epidemiology and biostatistics was organised at the end of 
the year by TAIEX (9), in cooperation with the EMCDDA and the Croatian Office for 
Combating Drug Abuse in Zagreb. Here, 47 national experts were trained in DRID data 
collection and PDU estimates.
In addition, as part of its international cooperation strategy, the EMCDDA implemented 
capacity-building activities for non-EU countries linked to key indicators and reporting.
Two events in 2013 were particularly relevant for countries outside the EU (for details, see 
Main area 8): a Reitox Academy training course on ‘Contemporary approaches to drug 
monitoring’, organised with the First Faculty of Medicine, Charles University, Prague 
(April), for 23 attendees from eight IPA countries; and a Reitox Academy on the prevention 
of infectious diseases among people who use drugs (October), involving 20 participants 
from five IPA countries.
(9) TAIEX: Technical Assistance and Information Exchange Instrument of the European Commission.
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Network development
A transversal priority for 2013 was the strengthening of the EMCDDA’s networks of 
experts, which contribute, together with the NFPs, to the information and knowledge base 
the agency has built over the years.
A major development here was a new way of organising the annual expert meetings on 
the key epidemiological indicators.
To this end, the Centre organised a week-long event on ‘Measuring, understanding and 
responding to drug problems in Europe’ in September. This included a meeting on the 
future of treatment monitoring, the TDI annual expert meeting and the PDU annual expert 
meeting. Through this event, the agency sought to rationalise each meeting and create 
more cross-indicator analysis, hence strengthening the networks of excellence developed 
over the last decade.
The two other annual expert meetings, on DRD and DRID, were held at the same time in 
order to be more efficient.
In total, more than 250 experts attended these meetings.
Enhancing analysis
The main goal in the 2013–15 work programme is to provide an improved overview of the 
European drugs situation by enhancing the epidemiological analysis of certain key 
indicators.
To help meet this goal, five outputs were published in 2013: a Paper on Co-morbid 
substance use and mental disorders in Europe: a review of the data (10); along with PODs 
on Trends in heroin use in Europe — what do treatment demand data tell us? (11); 
Preventing overdose deaths in Europe (12); Characteristics of frequent and high-risk 
cannabis users (13); and Emergency health consequences of cocaine use in Europe (14).
Finally, the EMCDDA participated, together with ECDC, in a regional HIV risk assessment 
exercise launched in April. The joint risk assessment report was published in 
Eurosurveillance (15). The third joint ECDC and EMCDDA meeting on detecting and 
responding to outbreaks of HIV among people who inject drugs took place in November. 
This provided a platform for information exchange, namely linked to current HIV outbreaks 
in Greece and Romania, whilst strengthening the capacity of all participating countries to 
monitor and prevent further HIV infections in this population group.
(10) Available at emcdda.europa.eu/publications/emcdda-papers/co-morbidity
(11) Available at emcdda.europa.eu/topics/pods/trends-in-heroin-use
(12) Available at emcdda.europa.eu/topics/pods/preventing-overdose-deaths
(13) Available at emcdda.europa.eu/topics/pods/frequent-cannabis-users
(14) Available at emcdda.europa.eu/topics/pods/cocaine-related-emergencies
(15) Available at eurosurveillance.org/ViewArticle.aspx?ArticleId=20648
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I  Monitoring demand reduction responses applied to drug-related problems (Main area 3)
Describing the demand reduction measures that reporting countries take to address drug 
problems is an essential part of the EMCDDA’s work. These measures span prevention, 
treatment, harm reduction and social reintegration. Historically, the focus of our work in 
this area has been to provide a descriptive analysis of the services available.
In 2013, we extended the analyses to cover the availability, coverage and quality of 
interventions delivered across Europe. This was a very productive year, resulting in seven 
new outputs, five expert meetings and three training events to enhance country capacity 
for monitoring drug responses in the region and beyond.
I Main highlights and achievements from the area
Prevention
In the prevention area, online resources were developed, including a new dedicated 
module in the Best practice portal.
The website was enriched with the results of the expert meeting on ‘Brief intervention and 
motivational interviewing for young alcohol and cannabis users’ in January, where 
European experts discussed the knowledge gaps that exist on these topics, which could 
be important for policy development.
Another prevention area in need of attention is coordinated programming. The agency 
organised an expert meeting, ‘Prevention systems: how to transform evidence into 
practice’, to explore how the evidence in prevention can be applied in prevention policy 
and from there in prevention practice.
A useful resource for practitioners and those working in the field is the European drug 
prevention quality standards: a quick guide (16), published in October. This product 
provides practical information on prevention quality standards to those working outside 
the European Union. It includes a description of the eight stages involved in the drug 
prevention cycle, along with a self-reflection checklist that can be used when planning 
and implementing prevention activities.
Furthermore, the EMCDDA Thematic paper North American drug prevention programmes: 
are they feasible in European cultures and contexts? (17) was published in June. It 
presents experiences of adapting and implementing four innovative and proven North 
American drug prevention programmes in Europe, showing the clear potential of 
transferring such programmes and avoiding the cliché of culture as a barrier to 
implementation.
Another key resource is the Thematic paper Drug prevention interventions targeting 
minority ethnic populations: issues raised by 33 case studies (18), released in April. It 
contains the results of a study that examined drug prevention interventions for minority 
(16)  Available at emcdda.europa.eu/publications/adhoc/prevention-standard in a range of EU and non-EU languages.
(17)  Available at emcdda.europa.eu/publications/thematic-papers/north-american-drug-prevention-programmes
(18)  Available at emcdda.europa.eu/publications/thematic-papers/prevention-minority-ethnic-populations
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ethnic populations in 29 European countries. A total of 33 interventions were reported to 
the study and the issues they raise are presented and discussed in the paper. The results 
will inform the EMCDDA’s plans for 2013–15 in terms of monitoring drug prevention 
interventions particularly in three areas: data collection, design and quality, and the 
dissemination of knowledge.
Treatment, harm reduction and social reintegration
To meet the Centre’s top priority of developing its online resources, the Health and social 
responses profiles (19) were launched with the EDR. These country-by-country ‘integrated 
responses profiles’ try to answer the question: how are countries in Europe responding to 
drug use in the areas of treatment, harm reduction, social reintegration and the prison 
environment?
The profiles were presented at a workshop on sharing evidence to improve addiction 
prevention and harm reduction hosted by the EMCDDA in November, organised by the 
Consumers, Health and Food Executive Agency (CHAFEA) (formerly known as the 
European Agency for Health and Consumers — EAHC), in collaboration with the EC. The 
event was attended by 24 European experts working on projects relating to drug and 
alcohol addiction and prevention and harm reduction in nightlife settings. Discussions 
focused on closing information gaps, improving processes for validating data at national 
level and increasing the visibility of the profiles.
As already mentioned, a key event in 2013 was the first EMCDDA week on ‘Measuring, 
understanding and responding to drug problems in Europe’ (see also Main area 2), which 
gathered experts from across the European Union, as well as the Russian Federation, 
South Africa, the United States and international organisations. This was the agency’s first 
treatment-focused meeting following its new strategy on treatment data collection and 
analyses, published in April (20). The strategy provides a framework for data collection on 
treatment responses to drug use in Europe and aims to ensure that maximum analytical 
value is derived from all aspects of treatment monitoring, to enhance the agency’s role in 
the dissemination of best practice.
Following an expert meeting, a European Facility Survey Questionnaire (EFSQ) was 
prepared, to collect information on drug treatment facilities in Europe in order to improve 
our understanding of the availability of services.
Another seminal publication is the Models of addiction (21) Insights published in June. 
This comprehensive report contains a critical review of existing addiction theories and 
explores how these can be organised into an overarching structure to inform how we 
assess, prevent and treat addictive behaviours. The model presented is not limited to illicit 
drugs, but can also be applied to alcohol, tobacco and even non-pharmacological 
addictions, such as gambling or compulsive use of the Internet.
Hepatitis C treatment for injecting drug users (22) (POD) presents some of the advances in 
treating the most common infectious disease among injecting drug users in Europe today, 
including a new generation of medicines.
(19) Available at emcdda.europa.eu/countries/hsr-profiles
(20) Available at emcdda.europa.eu/publications/treatment-strategy
(21) Available at emcdda.europa.eu/publications/insights/models-addiction
(22) Available at emcdda.europa.eu/topics/pods/hepatitis-c-treatment
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A national Reitox Academy on innovative approaches in harm reduction in December 
(Austrian NFP) brought together 22 participants, who were presented with the most 
recent information on, for example, best practice in provision of naloxone to prevent 
drug-related deaths and how to promote opioid substitution treatment through low-
threshold services.
Best practice
Identifying best practice and promoting information and knowledge sharing with the 
scientific community and professionals working in the drugs field are two fundamental 
tasks for the EMCDDA.
This area progressed significantly in 2013. Overviews of evidence on three media 
campaigns — the prevention of illicit drug use in young people; slow release oral 
morphine as maintenance therapy for opioid dependence; and methadone at tapered 
doses for the management of opioid withdrawal — were conducted and results published 
as scientific articles (see Annex 3: Outputs and products).
Furthermore, the use of mass media campaigns in drug prevention was further explored 
via the online analysis ‘Can mass media campaigns prevent young people from using 
drugs?’ (23), published in May as a POD, to support policy debate.
Developments to the Best practice portal (24), in line with our new communication 
strategy (see Main area 9), included improving its structure and usability. Content was 
provided by an expert meeting in October where participants, including DECIDE 
(Developing and evaluating communication strategies for supporting informed decisions 
and practice based on evidence) experts and EMCDDA staff, exchanged experience and 
shared best practice on how to communicate evidence to a varied audience.
The Centre also continued to disseminate knowledge on best practice in 2013. A high 
point was the national Reitox Academy on ‘Best practices in prevention’ organised by the 
Maltese NFP in October. This training course, attended by 23 experts, was a forum to 
share approaches and best practice in drug prevention, as well as to provide participants 
with the skills needed to critically assess the impact of drug prevention programmes, 
based on available evidence.
Other events on this topic included a special session during the ‘Course on contemporary 
approaches of drug monitoring’ in April (see Main area 8); and a workshop during the 
Reitox week (see Main area 10). The Centre also provided support to international projects 
such as COPOLAD and the European project ‘Improving quality in HIV prevention’.
The Centre also considered the gaps that exist in the evidence available for interventions. 
Based on a project started in 2012, the Scientific Committee completed a Research 
Priority framework and submitted it to the HDG in June 2013 on behalf of the EMCDDA 
for consideration during the annual dialogue on research (see Main area 7).
(23) Available at emcdda.europa.eu/topics/pods/mass-media-campaigns
(24) Available at emcdda.europa.eu/best-practice
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I  Monitoring drug supply and supply reduction interventions (Main area 4)
The development of new indicators in the field of drug supply and supply reduction and 
the launch of the first strategic overview of drug markets in Europe were the main 
highlights of our work in this area in 2013.
One objective of the EU drugs action plan 2013–16 is to ‘enhance effective law 
enforcement coordination and cooperation within the EU to counter illicit drug activity, in 
coherence, as appropriate, with relevant actions determined through the EU policy cycle’. 
Action 16 calls on the Commission, Member States, the Council, EMCDDA and Europol to 
‘develop and progressively implement key indicators on drug supply by standardising, 
improving, and streamlining data collection in this field, building on currently available 
data’. Therefore, in collaboration with the EC and Europol, the EMCDDA scaled up 
activities in 2013. This included the launch of two sub-indicators (drug seizures and drug 
production facilities) and the creation of the EMCDDA reference group on drug supply.
Furthermore, the EMCDDA and Europol launched a strategic overview which placed 
drugs within the larger context of illicit markets and organised crime.
The EMCDDA also supports the EU policy cycle for organised and serious international 
crime 2013–17 within COSI. In particular, the EMCDDA contributes in the field of 
synthetic drugs (including NPS), cocaine and heroin trafficking, and provides support to 
Europol for the follow-up of activities initiated under the previous policy cycle on the 
reporting of synthetic drug production sites.
I Main highlights and achievements from the area
The key event of the year was the launch in January 
of the first EMCDDA–Europol EU drug markets 
report: a strategic analysis (25) at a press conference 
held by Commissioner Malmström, EMCDDA 
Director Wolfgang Götz and Europol Director Rob 
Wainwright.
In terms of key indicators in the areas of drug 
markets, drug-related crime and drug supply 
reduction, priority was given to the sub-indicators 
on drug seizures and drug production facilities.
We made considerable progress in the drug 
seizures area, with the launch of a mapping exercise in November. This will develop in 
2014 and will inform the EMCDDA’s proposal for a revised reporting instrument on drug 
seizures (see below) in 2014.
In the area of drug production facilities, the EMCDDA is developing a revised reporting 
instrument on cannabis cultivation, and contributes to the work on synthetic drugs 
production sites carried out by Europol. In 2013, a pilot study to investigate reporting 
practices on cannabis cultivation was launched.
(25) Available at emcdda.europa.eu/publications/joint-publications/drug-markets
EMCDDA Director Wolfgang Götz, 
Commissioner Cecilia Malmström and 
Europol Director Rob Wainwright at the 
press conference to launch the EU drug 
markets report, Brussels, 31 January 
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The first comprehensive overview of illicit drug markets in the European Union, the European 
drug markets report covers issues such as production, consumer markets, trafficking, 
organised crime and policy responses, along with a review of the markets for heroin, cocaine, 
cannabis, amphetamine, methamphetamine, ecstasy and NPS. It concludes with concrete 
action points for the areas where the current EU response to the drugs market and its 
consequent harms may be improved.
An essential reference tool for law enforcement professionals, policymakers, the academic 
community and the general public, the report combines Europol’s strategic and operational 
understanding of trends and developments in organised crime with the EMCDDA’s ongoing 
monitoring and analysis of the drugs phenomenon in Europe and beyond.
In recognition of its value, the report was nominated by the American Library Association in 
the International category for the 2012 list of notable government documents (see Main 
area 7).
During the course of the year, two meetings took place with Europol to develop a 
coordinated approach for reporting on synthetic drug production sites and data 
validation. A tool to improve data collected on dismantled synthetic drug laboratories was 
designed, to be further developed in 2014.
Moreover, current trends in illicit synthetic drug production in Europe and some of the 
challenges faced by law enforcement bodies were described in the POD Synthetic drug 
production in Europe (26).
Pilot work was also carried out on drug prices and drug availability. Improving reporting on 
drug purity was discussed at a forensic drug experts meeting organised by the EMCDDA 
in October.
Drug law enforcement activity targets the supply of drugs and provides most of the data 
that inform our understanding of drug supply in Europe. In 2013, the EMCDDA released a 
Paper on Europe’s specialised drug police units called Drug squads: units specialised in 
drug law enforcement in Europe. This presented the results of a survey covering 26 
European countries, analysing for the first time how drug law enforcement is organised.
Vital to developing drug supply indicators is cooperation with partners. In 2013, along 
with the work conducted with Europol, new initiatives were developed with Eurojust and 
UNODC. A Memorandum of Understanding (MoU) is currently under preparation with 
Eurojust. Regarding cooperation with UNODC, the EMCDDA hosted the third informal 
meeting of the UNODC Afghan Opiate Trade Project (AOTP) for 30 leading specialists 
from EU Member States, Turkey, Russia, the United States and international organisations 
such as the African Union.
Network development is also central to scaling up efforts in this area. In 2013, the 
EMCDDA set up a reference group on drug supply, including representatives from each 
Member State, the EC (DG Home Affairs and Eurostat), Europol and Eurojust. The group 
met for the first time in December.
Cooperation with CEPOL was also enhanced in 2013 (see Main area 8). One highlight was 
the study visit of 21 European senior police officers to the EMCDDA, in order to learn 
more about the EU drugs strategy, its action plans and their consequences for law 
enforcement cooperation in Europe; the state of the drugs problem in Europe and the 
EMCDDA’s mandate, working methods and products.
(26) Available at emcdda.europa.eu/topics/pods/synthetic-drug-production
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In 2013, the agency also fulfilled its tasks within the OAP for 2012–13 (new policy cycle 
within COSI), namely in the field of synthetic drugs, and provided input to the definition of 
priorities for the next policy cycle.
Furthermore, the EMCDDA published a Paper on Drug supply reduction and internal 
security policies in the European Union: an overview (27). Focusing on the EU’s internal 
security situation, this paper elaborates who sets policy, existing legal and funding bases 
and main priorities in this area.
I  Monitoring new trends and developments and assessing the risks of new substances (Main area 5)
The EMCDDA has a vital role to play in the detection and assessment of new drugs in the 
European Union under the terms of Council Decision 2005/387/JHA on the information 
exchange, risk assessment and control of NPS. As in previous years, in 2013 the EMCDDA 
oversaw the implementation of the EWS, together with Europol and the Reitox network.
However, 2013 was a particularly demanding year. The number of NPS appearing on the 
market continued the upward trend started in previous years; moreover, these substances 
raised more public health concerns than ever before. Four data collection exercises were 
launched and EMCDDA–Europol Joint Reports were prepared and sent to the EC, the 
Council and the EMA (up from only three cases for the entire period 2010–12). The 
follow-on from this will have a major impact on our work in 2014.
We also continued to monitor new developments in 2013, through fine-tuned Internet 
snapshot and trendspotter methodologies and the development of new sources for 
investigation, such as wastewater analysis.
I Main highlights and achievements from the area
Implementation of the early-warning mechanism
Eighty-one NPS were formally notified in 2013, representing an increase of 11 % from 2012 
(73 substances). Subsequently, 86 new substance profiles were created and included in the 
European database on new drugs (EDND). A total of 444 reporting forms (new substances, 
first notifications and significant updates from Member States) were processed by the EWS 
in 2013.
During 2013, 16 public health-related alerts were notified to EWS correspondents.
One risk assessment exercise, on 5-(2-aminopropyl)indole (5-IT), was carried out by the 
extended Scientific Committee, and EMCDDA–Europol Joint Reports were prepared on four 
NPS: methoxetamine, AH-7921, 25I-NBOMe and MDPV.
The 13th annual meeting of the Reitox EWS network took place in June, alongside the 
Europol second law enforcement meeting on NPS. Over 70 representatives of the Reitox 
and Europol networks from the 30 EMCDDA reporting countries attended the meeting.
(27) Available at emcdda.europa.eu/publications/emcdda-papers/sr-internal-security
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The meeting was followed by the third international multidisciplinary forum on new drugs, 
attended by 130 participants, including the EWS network members, members of the 
Europol national units, representatives from the EC and the EMA, and experts from 10 
non-EU countries.
The EMCDDA–Europol 2012 Annual report on the implementation of Council Decision 
2005/387/JHA (28) was prepared by the two agencies and published in May. It includes 
information on the activities conducted in response to the decision, as well as the year’s 
coordination activities.
A risk assessment for 5-IT was conducted by the Scientific Committee on 11 April, based 
on the EMCDDA–Europol Joint Report published in February 2013. The Risk Assessment 
Report and the technical annexes were sent to the European Council and the EC on 17 
April.
On 7 October, the EMCDDA launched the information collection for the preparation of 
Joint Reports on four NPS: methoxetamine, AH-7921, 25I-NBOMe and MDPV. For this 
exercise, a revised questionnaire was tested and launched. The four Joint Reports were 
completed and submitted to the usual authorities in December. In January 2014, the 
Council informed the Centre that four risk assessment exercises now need to be 
conducted.
One major outcome of the Centre’s work with its EWS partners was the Decision of the 
Council of the EU (29) to subject the stimulant drug 4-methylamphetamine (4-MA) to 
‘control measures and criminal penalties’ throughout the Union. This decision was based 
on the findings of a formal risk assessment report from 2012.
The EMCDDA also continued to provide support to the EC during the drafting phase of the 
new legal instrument on NPS, which will replace the current Council Decision.
The EMCDDA played a major role in the Second international conference on novel 
psychoactive substances, held in September in Swansea, by presenting keynote 
speeches and chairing several sessions.
A new analysis on Synthetic cannabinoids in Europe (30) was published as a POD. This is 
the largest group of compounds currently monitored in Europe by the EWS. The POD 
presents current knowledge available regarding these substances, as well as trends in 
production, availability and use.
The information exchange with the EMA and the EU pharmacovigilance system on 
medicines and substances with medicinal properties continued in 2013. The EMCDDA 
and the EMA met in April, to discuss the data available on the misuse and abuse of 
medicinal products. The 2013–15 strategy and work programme sets the task of defining 
a conceptual framework for monitoring the misuse of medicines in the context of 
polydrug use. In 2013, a CUP was set up with this purpose (see Main area 7).
In terms of strengthening partnerships, the EMCDDA participated as an observer in the 
annual meeting of the European Network of Forensic Science Institutes in May. This 
network is crucial in identifying new drugs and trends within the EU. Similarly, the 
EMCDDA organised a forensic drug experts meeting in October on the reporting of data 
(28) Available at emcdda.europa.eu/publications/implementation-reports/2012
(29) Adopted at the Justice and Home Affairs Council, 7–8 March 2013, Brussels.
(30) Available at emcdda.europa.eu/topics/pods/synthetic-cannabinoids
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on drug purity and composition of illicit tablets in order to inform the forthcoming 
introduction of EU-level supply indicators (see Main area 4); and to explore the options to 
increase interaction between the forensic community and the EWS.
The methodology for monitoring the Internet was improved in 2013 and a new snapshot 
exercise was carried out in February, leading to a list of webpages selling new drugs.
In addition, the EMCDDA is advisor to the iTrend (Internet Tools for Research in Europe on 
New Drugs) EU-funded project. One objective of this project is to monitor online shops 
selling new drugs. The kick-off meeting for the project took place in April.
Training on NPS was also delivered during the Reitox Academy held in April. A pilot 
Internet snapshot in seven Balkan languages was implemented at the event (see Main 
area 8) and at least one website selling psychoactive substances was identified for each 
of the languages under scrutiny.
To help improve the monitoring of new drugs and links with epidemiological data sources 
and expert networks, a new EMQ module on new drugs was developed (see also Main 
area 2) and the module has already been included in some new GPSs).
Emerging trends
Detecting new trends is an important part of the agency´s work, to make sure our 
monitoring systems keep pace with changes in the drugs situation. To complement work 
already under way, a new CUP was established in 2013 (see also Main area 7), to 
coordinate activities in the area of identifying, tracking and reporting on new trends.
As a response to recent developments, in July 2013, the EMCDDA launched a 
trendspotter study on methamphetamine trends in Europe, which culminated in an expert 
meeting. A paper will be released on this topic in 2014.
Another recent trend is the monitoring of drug residues in wastewater, in order to estimate 
drug consumption at population level. Following work started in 2012 with the SEWPROF 
project (31), the conference ‘Testing the waters: first international multidisciplinary 
conference on detecting illicit drugs in wastewater’ was co-organised by the EMCDDA 
and SEWPROF in May. This event brought together 90 international experts from 20 
countries working in: drug epidemiology, pharmacokinetics, statistics, forensic science, 
analytical chemistry and environmental engineering (32).
I  Improving Europe’s capacity to monitor and evaluate policies (Main area 6)
Since its creation, the EMCDDA has monitored various aspects of drug policies. The ELDD 
and network of legal correspondents constitute the main resources supporting the 
EMCDDA’s reporting on drug laws.
(31)  SEWPROF (Sewage profiling at the community level) is a research project funded by the European Commission, 
Marie Curie Actions, Seventh Framework Programme and Initial Training Network.
(32) Conference documents available at emcdda.europa.eu/wastewater-analysis
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I Main highlights and achievements from the area
The 14th meeting of the ELDD’s legal correspondents took place in October. The two-day 
meeting brought together representatives from the 30 EMCDDA reporting countries to 
exchange information on national and EU legal updates, including laws controlling new 
drugs. The meeting covered a broader policy agenda this year, including legislative and 
strategic developments, as well as public expenditure.
The EMCDDA Paper Drug policy advocacy organisations in Europe (33) was published in 
December. Some 218 civil society organisations actively seeking to influence drug policy 
were identified through an Internet search in English, French and Spanish, combined with 
information from national sources in 30 countries. The Paper categorises the 
organisations, looking at their advocacy objectives and orientations, how they pursue 
these, and at what political levels they operate.
Following the launch in 2011 of the ´Drug policy profiles´ series, the second profile, on 
Ireland, was published in February (34). The report explores: the country’s national 
strategies; the legal context within which they operate; the public funds spent, or 
committed, to implement them; and the political bodies and mechanisms set up to 
coordinate the response to the problem.
A core task for the EMCDDA is the provision of data and expertise for the evaluation of 
the new EU drugs strategy and its two action plans. As background to this work, the POD 
entitled The new EU drugs strategy (2013–20) (35) presents the strategy’s main features 
and how it aims to address Europe’s changing drugs problem. The first action plan 
(2013–16) was adopted in June. The EMCDDA is defined as the reporting agency for 23 
actions and as an actor in 15 cases.
The Centre also provides support to experts and policymakers in the area of drug policy 
evaluation. In 2013, Germany, Estonia, Ireland, Croatia, Lithuania, Portugal, Slovenia and 
non-EU countries such as Turkey and Japan were given such support.
I  Scientific coordination, research and content support  (Main area 7)
An ongoing commitment to improving the scientific quality of our work is a prerequisite for 
fulfilling our role as a centre of excellence for the collection, analysis and dissemination of 
drug-related information. It is therefore a primary objective in the EMCDDA’s 2013–15 
strategy and work programme.
Top priorities in 2013 were to ensure the development, quality and coherence of the 
agency’s information collection and reporting system, improve internal coordination and 
enhance transversal work.
(33) Available at emcdda.europa.eu/publications/emcdda-papers/advocacy
(34) Available at emcdda.europa.eu/publications/drug-policy-profiles/ireland
(35) Available at emcdda.europa.eu/topics/pods/eu-drugs-strategy-2013-20
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I Main highlights and achievements from the area
Scientific coordination
In order to develop and improve the agency’s information collection and reporting system, 
an overhaul of tools started in 2011 focusing on the national reporting package and the 
definition of a comprehensive quality assurance framework for our scientific work.
The need to modify the national reporting package gained importance in 2013 as a result 
of the risk of a cut in funds for 2014. A proposal for a revised package was developed by 
the EMCDDA, in close consultation with the NFPs (see Main area 10), and work to 
implement this will run for the new few years.
Development of a quality assurance framework for our scientific work is one of the key 
tasks of the QA CUP, set up in 2013. The CUP started by identifying and mapping quality 
assurance projects already in place at the EMCDDA, giving a ‘quality assurance status’ to 
each one, based on relevance for the 2013–15 work programme. In 2013, the group 
developed a proposal for a statistics code of practice (see Main area 1) and a follow-up 
action plan for the systemic review of tools project.
Two other CUPs were established in 2013: CUP Medicines (misuse of medicines in the 
context of polydrug use) (see Main area 5) and CUP New trends (see Main area 5). In addition, 
the mandate of the CUP on treatment created in 2010 was renewed (see Main area 3).
The EMCDDA has a duty to share knowledge, and partnerships with academic initiatives 
help us to achieve this. One example is the summer school project. Within the partnership 
launched in 2012 with the Instituto Superior das Ciências do Trabalho e da Empresa – 
Instituto Universitário de Lisboa (ISCTE–IUL), a second summer school, on ‘Drugs in 
Europe: supply, demand and public policies’, took place in July 2013. This edition was 
attended by 28 students (25 from 11 EU Member States and three from third countries). 
Students who filled in the evaluation questionnaire following the event replied that the 
school had met their expectations, and 95 % of them thought that the information 
received during the school would be very useful for their professional/academic life.
Another channel for knowledge dissemination is scientific publishing. In addition to the 
large number of publications released in 2013, 34 scientific articles were published, 
representing an increase of almost 50 % from 2012 (23 articles). The complete list of our 
outputs is presented in Annex 3.3637
As further confirmation of the Centre’s scientific excellence, three EMCDDA publications 
were recognised among the ‘Notable Government Documents of 2012’ by the American 
Library Association (ALA), as follows: EU drug markets report: a strategic analysis (see Main 
area 4), Cannabis production and markets in Europe (36) (Insights series, 2012) and New 
heroin-assisted treatment: recent evidence and current practices of supervised injectable 
heroin treatment in Europe and beyond (37) (Insights series, 2012).
Publications are nominated which meet or surpass a range of criteria, including the lasting 
value and reference and bibliographic value of the publication; the degree to which the 
document expands knowledge or shows innovation; and the extent to which the document 
enhances quality of life and furthers understanding of government processes or functions or 
of an agency’s mission. The physical appearance, browsability, searchability and usability of 
the publication are also acknowledged, as is its appeal to a broad audience.
(36) Available at emcdda.europa.eu/publications/insights/cannabis-market
(37) Available at emcdda.europa.eu/publications/insights/heroin-assisted-treatment
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Drug-related research
The EMCDDA continued to follow closely 
both EU and national drug-related research 
projects, presenting the information on its 
website (38) and dedicated intranet pages.
The third EMCDDA Scientific paper award 
ceremony took place in November, as a 
fringe event at the Scientific Committee 
meeting. The prize celebrates scientific 
writing and distinguishes high-quality 
research in the field of illicit drugs. In 2013, 
there were four winners, based in Germany, 
Austria and Norway and at the EMCDDA.
In 2013, the agency continued to contribute to studies and research. Advised by its 
Scientific Committee, the EMCDDA supports the EC in the preparation for the Council of 
the EU’s annual dialogues on drug-related research (39). The results of the research gap 
analysis started in 2012 and of the Research Priority Framework were discussed at the 
Scientific Committee meeting in April. The final outcome was submitted to the HDG on 
behalf of the EMCDDA for consideration during the 2013 annual dialogue on research.
For the first time, the EU action plan on drugs 2013–16 mentions the EMCDDA´s 
Scientific Committee as an actor in three actions related to drug research in Europe. The 
full implications of this will be addressed by the incoming Scientific Committee in 2014 
(see Main area 10).
Concerning the NFPs, a forum was organised during the Reitox week in May, where recent 
developments in the area of drug-related research were discussed, along with the 
Research Priority Framework.
(38) Available at emcdda.europa.eu/topics/research
(39)  Council of the European Union, ‘Council conclusions on strengthening EU research capacity on illicit drugs’, 
Brussels, 7 December 2009.
This year’s award for outstanding research was given 
to four authors
3
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Cooperation with key partners is a cornerstone of the agency’s mandate. These include 
EU institutions, national policymaking bodies, international organisations, civil society and 
third countries. Through its international cooperation activities, the EMCDDA provides 
expertise on drug issues, whilst participating in international projects and presenting a 
coordinated and coherent approach to both regional and global developments.
I Main highlights and achievements from the area
EU institutions
In 2013, the EMCDDA continued to support drug policy dialogue at EU level by providing 
its expertise to the EP, the Council of the EU and the EC.
Regarding collaboration with the EP, as already mentioned, two major publications — the 
EU drug markets report: a strategic analysis (see Main area 4) and the European Drug 
Report (see Main areas 1 and 9) — were presented by the Director to the LIBE Committee 
in Brussels, on 20 February and 30 May 
respectively.
Another important event was the visit of 
three LIBE Committee members to our 
offices in July. Barbara Dührkop Dührkop 
(Spain) and Carla Rossi (Italy), the two 
members of the EMCDDA’s Management 
Board who were designated by the EP, also 
accompanied the delegation, and João 
Goulão, Chairman of the EMCDDA’s 
Management Board, joined the group.
The EMCDDA also maintained strong 
relations with the EP on issues such as the 
new legal framework on NPS; the Directive 
on provisions on constituent elements of 
criminal acts and penalties in the field of 
illicit drug trafficking; and the launch of the 
Recovered Users Network (RUN), hosted by 
a member of the LIBE Committee.
CHAPTER 3
Cooperation and 
collaboration with key 
partners (Main area 8)
João Goulão, Chairman of the EMCDDA Management 
Board, Wolfgang Götz, EMCDDA Director, Ioan Enciu 
MEP (Romania), Marco Scurria MEP (Italy) and Carlos 
Coelho MEP (Portugal) during the visit of the European 
Parliament’s LIBE Committee to the EMCDDA’s offices 
in July
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In terms of cooperation with the Council, it is important to note the Director’s 
presentation of the EDR to the Council of JHA Ministers on 6 June in Luxembourg.
Furthermore, the EMCDDA participated in 11 HDG meetings during the year. One 
highlight was the presentation of the ‘EMCDDA contribution towards a methodological 
framework for monitoring drugs and prison in Europe’ (40) made at the February meeting. 
The EMCDDA also attended various dialogues (with Russia, the United States of America, 
Peru), meetings of National Drug Coordinators, EU CELAC, the Central Asian Partnership 
and the Dublin Group. A total of 25 presentations were delivered by the agency and a 
comprehensive list of events attended by the EMCDDA can be found in Annex 4.
The EMCDDA also provided input to the meeting of the Committee on Political Affairs of 
the Euro-Latin-American Parliamentary Assembly (EuroLat) in July in Vilnius, where the 
EDR was presented.
As previously mentioned, the EMCDDA provides support to the EU policy cycle for 
organised and serious international crime 2013–17 within COSI. In 2013, the agency 
fulfilled its tasks regarding synthetic drugs under the OAP for 2012–13 and provided input 
to the definition of the priorities of the next policy cycle (see Main area 4).
Furthermore, the EMCDDA provided input to the Council Conclusions on improving the 
monitoring of drug supply in the EU (41), adopted at the Economic and Financial Affairs 
Council meeting in November. Based on the findings from the drug markets report, the 
document stresses the importance of collecting accurate, reliable and comparable data 
on drug supply in order to better assess the drugs situation, the dynamics of the illicit 
drugs market, the burden of drug-related crime and the effectiveness of supply-oriented 
policies.
Throughout the year, the EMCDDA provided technical input to the EC on a range of issues, 
including: the new legal framework on NPS (see Main area 5); policy dialogues between 
DG Home and Member States; follow-up of the project on Minimum Quality Standards in 
Drug Demand Reduction (EQUS); the EU action plan on HIV/AIDS (follow-up); the EC’s 
evaluation of CADAP 5; and the EU–Central Asia political dialogue.
The EMCDDA hosted a workshop on sharing evidence to improve addiction prevention 
and harm reduction in November. This was organised by the Consumers, Health and Food 
Executive Agency (CHAFEA), in collaboration with the EC (see Main area 3).
EU agencies and international organisations
In 2013, the EMCDDA continued to collaborate with other EU agencies, actively taking 
part in inter-agency networks and meetings of the JHA agencies cluster.
The Director attended the three Heads of agencies network meetings and the Centre’s 
staff contributed to the work of inter-agency networks, including the EU network of 
scientific advisors (EU–ANSA); the Heads of administration network; the ICT Managers’ 
network (ICTAC); the Inter-agency accountants’ network (IAAN); the Heads of 
communication and performance development networks; and the Inter-Agency Legal 
Network (IALN).
(40) Available at news-europa.eu/employment-social-affairs/item/42323-consilium-advanced-search
(41) Available at consilium.europa.eu/uedocs/cms_data/docs/pressdata/en/jha/139606.pdf
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The Centre also continued to strengthen cooperation with the European Maritime Safety 
Agency (EMSA), our neighbour agency in Lisbon, identifying areas for synergy (human 
resources management, logistics and infrastructure management, information and 
communication technologies). Actions in these areas will be further developed in 2014.
Along the same lines, contacts with FRA were initiated in 2013 with a view to sharing 
experience and building synergies in the area of performance management development.
Our collaboration with other agencies continued to gain momentum. The main agencies 
concerned were Europol (see Main areas 4 and 5), CEPOL and Eurojust (see Main area 4), 
the EMA (see Main area 5) and ECDC (see Main areas 2 and 3).
Cooperation with international organisations was also enhanced in 2013, in particular 
with UNODC, WHO and CICAD. Cooperation with UNODC is governed by a joint work 
programme. A highlight of 2013 was the third informal meeting of the UNODC’s AOTP 
(see Main area 4) hosted by the EMCDDA, and other key events, such as the meeting of 
the Heads of National Drug Law Enforcement Agencies (HONLEA) in July and UNODC’s 
international expert consultations on NPS in September.
Recent cooperation with WHO Europe focuses on prison and infectious diseases whereas 
cooperation with WHO headquarters in Geneva centres on the quality standards of 
interventions and the monitoring of treatment systems. In 2013, EMCDDA staff took part 
in the ‘Meeting of the Technical Advisory Group on Alcohol Epidemiology’ in Geneva and a 
meeting with the coordinator for the management of substance abuse in WHO’s Vienna 
office.
In 2013, the EMCDDA further enhanced its cooperation with the Council of Europe 
Pompidou Group.
In terms of collaboration with CICAD, Ambassador Paul E. Simons, Executive Secretary, 
visited the EMCDDA’s headquarters and the two bodies signed a new work programme 
(see section on activities of the Director).
Furthermore, in the autumn COPOLAD collaborated with the Centre on a thematic 
twinning course on ‘Analysis and interpretation of drug-related data’, attended by 28 
experts from 15 Central American countries and experts from European countries and 
CICAD. Discussions focused on the challenges in compiling and disseminating drug-
related data and in developing drug policies.
Candidate and potential candidate countries
Cooperation with candidate and potential candidate countries continued in 2013 within 
the framework of the IPA 4 technical assistance project for preparing beneficiary 
countries (Iceland, the former Yugoslav Republic of Macedonia, Albania, Bosnia and 
Herzegovina, Montenegro, Serbia, and Kosovo (42) for their participation in the work of the 
EMCDDA.
(42)  This designation is without prejudice to positions on status, and is in line with UNSCR 1244 and the ICJ Opinion on 
the Kosovo declaration of independence.
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An external evaluation of the IPA project was commissioned by the EC and carried out by 
independent evaluators in March. The evaluation report was very positive — the project 
implemented so far received top marks (‘very good’) for four out of the six criteria monitored 
(relevance, quality of design, efficiency, impact). The two remaining criteria were graded as 
‘good’.
An important component of the IPA project is capacity building. In 2013, this was mainly 
achieved through several Reitox Academies. One Academy, on ‘The European Union, the 
EU drugs policy and the enlargement process under the Lisbon Treaty’, was implemented 
jointly with the College of Europe in February. The training covered several aspects of the 
enlargement process, EU policies, strategies and action plans. Twenty-two participants 
representing all IPA 4 beneficiary countries attended the course.
The Reitox Academy training course on 
‘Contemporary approaches in drug monitoring’ was 
organised with the First Faculty of Medicine of 
Charles University in Prague in April. In total, 23 
representatives representing all eight IPA beneficiary 
countries and three representatives of EU Member 
States took part. The overall aim of the week-long 
training course was to train professionals on how to 
organise a drug information system, to collect, 
analyse and interpret drug-related data, and to 
provide their different audiences with information on 
the drugs situation.
The Academy on ‘Prevention of infectious diseases 
among people who use drugs’ took place in Sarajevo 
in October with 20 experts from Albania, Bosnia and 
Herzegovina, Kosovo, Montenegro and Serbia. This 
focused on policies and measures to prevent and 
control infectious diseases and other health 
consequences related to injecting drug use in the 
Western Balkan countries, along with key measures for prevention and service provision.
Furthermore, experts from IPA 4 beneficiary countries took part in various EMCDDA 
expert meetings, including the annual expert meetings on GPS, TDI and PDU (see Main 
area 2).
Other project results in 2013 included the assessment of forensic laboratory capacities 
carried out in five countries (Albania, Bosnia and Herzegovina, the former Yugoslav 
Republic of Macedonia, Serbia and Kosovo), to further develop data collection of DRD 
data; support for the implementation of GPS in three countries (Serbia, Kosovo and 
Albania); support for the implementation of TDI (ongoing in all IPA 4 beneficiary 
countries); and Country overviews for Albania, the former Yugoslav Republic of 
Macedonia, Serbia and Kosovo (in English and national languages), published as part of 
the EDR package (43).
(43) Available at emcdda.europa.eu/countries
Group photo from the Reitox Academy 
held in Bruges in February
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European Neighbourhood Policy countries and third countries
Professionals from five ENP countries (Armenia, Georgia, Israel, Moldova and Ukraine) 
and Russia attended the second Reitox week, and updated Country overviews for 
Ukraine, Georgia and Tajikistan were published online.
In 2013, the EC awarded the EMCDDA financing of EUR 450 000 for implementing a 
two-year technical assistance project in ENP countries. ‘Towards a gradual improvement 
of ENP partner countries’ capacity to monitor and to meet drug-related challenges’ will 
help strengthen the capacity of selected ENP partner countries (Armenia, Azerbaijan, 
Georgia, Israel, Moldova, Morocco, and Ukraine) to respond to new challenges and 
developments on the drugs situation. Implementation will start in 2014.
In July 2013, the Management Board mandated the EMCDDA Director to negotiate a MoU 
or cooperation agreement for formalising cooperation between the EMCDDA and the 
National Security Council of the Republic of Armenia. In August, a first draft was sent to 
the Secretary of the National Security Council for comments.
4
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CHAPTER 4 
Supporting the 
achievement of results
I  Communicating the EMCDDA’s findings to external audiences (Main area 9)
The EMCDDA recognises that investing in data collection and analysis is worthwhile only 
if it results in products that can be accessed by those who need them in an appropriate 
form and within an appropriate timeframe. Therefore, communication is one of our core 
activities, supporting our role as an information agency and helping to further our 
reputation as the reference point on drugs in Europe. The integrated communication 
strategy, adopted in 2012, sets out the fundamental principles for communicating our 
knowledge and presents the tools available to build and nurture relations with our 
stakeholders, target audiences and partners.
Activities in 2013 were guided by this strategy, which aims to ensure that communication 
activities are not an isolated function at project end, but an integral part of the agency’s 
scientific and technical work. At a time of heightened need for an efficient use of 
resources, this holistic and multidisciplinary approach pools scientific and technical 
expertise to produce pertinent and cost-efficient results. In 2013, a range of 
communication activities supported this aim, including publications (printed and web-
based), presentations, dissemination, media relations, public relations, events and 
marketing, and library services, in line with the priorities contained in the 2013–15 work 
programme.
I Main highlights and achievements from the area
Integrated communication infrastructure developed
Work to implement the integrated communication strategy (44) concentrated on defining 
efficient and quality-controlled workflows, ensuring an organic approach to product 
conception and improving timeliness through better planning. We began to work on 
performance indicators to help us better assess the impact of our activities.
The EMCDDA product range was reviewed and rationalised to achieve a better mix of 
print and online products, taking into account new information-seeking behaviours and 
the need to save costs. The range of product types has been simplified, the number of 
(44) Available at europa.eu/publications/communication-strategy
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printed products reduced, and publication formats adapted to better suit the content 
being presented. The design of all products was rethought and refreshed in the updated 
EMCDDA corporate identity. The brand refresh was launched according to plan on 28 May 
with the EDR package, and work to revamp all products, stationery and other outputs 
continued throughout the year.
In order to deliver a high-quality information service on drugs, emphasis must be placed 
on developing user-focused products tailored to the needs of stakeholders and target 
groups. With this in mind, stakeholder engagement is a key area of the new EMCDDA 
integrated communication strategy. A technical paper on audience engagement was 
prepared, and mapping of our stakeholders commenced with ‘academia’.
Finding an effective and sustainable linguistic strategy is an important element in the 
dialogue with our audiences. A reduced budget meant that translation decisions were 
based on overall impact, with a preference for shorter texts. However, we received an 
increasing number of requests from NFPs and other nationally based organisations for 
permission to translate EMCDDA titles — especially Manuals, Guidelines and Handbooks 
— and new translation guidelines were developed to deal with these requests. The 
glossary product continued with 37 new terms defined and sent for translation, and it was 
expanded to include Croatian.
Internal communication advanced with the finalisation of an internal communication 
strategy, which was redrafted to incorporate the results of the staff opinion survey. There 
was considerable development of the intranet as a main channel for sharing in-house 
information.
Publishing high-quality and timely products
Forty-one online and printed products were launched in 2013, including: the EDR 
package (Trends and developments report (in 23 languages), 11 PODs, Statistical bulletin, 
30 country overviews, Health and social responses profiles and 30 National reports); one 
Insights; one toolkit; three joint publications (two linked to Council Decision 2005/385/
JHA — see Main area 5); six Papers/Thematic papers; one Drug policy profile; one Data 
collection strategy; one brochure and one ad hoc publication; six institutional 
publications; and four issues of Drugnet.
Keeping abreast of the numerous products that the information agency produces has 
been greatly facilitated by a products database and monthly follow-up meetings that plan 
work and decide the best use of available resources (see also Main area 7).
The costs involved for the preparation and launch of the EDR in 2013 represented a 
substantial saving in relation to the cost of the former Annual report whilst providing a 
package that delivered better quality, variety and usability. The cost of this output 
dropped by more than half (from EUR 653 108 in 2012 to EUR 257 087 in 2013).
All products were disseminated via the EMCDDA website and social media channels, 
along with news releases to mark the launch of key products.
Increasing the relevance and impact of the EMCDDA’s online presence
The EMCDDA website is at the heart of activities planned for 2013–15, and work started 
on a number of parallel projects. An inventory of existing content was performed, for 
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further analysis in 2014. The look of the website was overhauled in line with the refreshed 
corporate identity, and findability of, content enhanced with a reconceived home page.
We improved access to the wealth of EMCDDA data by developing interactive products 
and data visualisations, e.g. the designed-for-the-web PODs and the Health and social 
responses profiles — incorporating the necessary quality controls.
We developed the audiovisual channel using in-house expertise and produced 13 videos 
that had attracted nearly 12 000 views by the end of the year. We also integrated our 
social media activities better with the website.
Implementing a new content management system underpins our ability to improve 
efficiency and performance in this area. We selected the tool Drupal for this purpose, 
following a study of the market.
Enhancing visibility, reputation and recognition
Some 30 staff members participated in the ‘Representing the EMCDDA’ programme, 
which is designed to boost the ability of staff to represent the agency externally and to 
communicate the EMCDDA’s mission.
The EMCDDA organised, or was represented at, several prominent events throughout the 
year. This included major international scientific conferences, such as Global Addiction 
2013 and the European Society for prevention Research (EUSPR), among others. In 
collaboration with neighbour agency EMSA, the Lisbon municipal authorities and the EP 
and EC offices in Lisbon, the agency opened its doors to the Lisbon public for a day on 18 
June, to mark the naming of the square where the agency has its headquarters as Praça 
Europa.
Furthermore, the agency had stands or displays at the 56th session of the Commission 
on Narcotic Drugs, the European Institutions Open Day and the European Scientific 
Conference on Applied Infectious Disease Epidemiology (ESCAIDE) 2013, to name but a 
few. Conference brochures and materials were developed to support the Second 
international conference on novel psychoactive substances in Swansea, the Third 
international multidisciplinary forum on new drugs and the Testing the waters conference. 
Annex 4 presents a comprehensive list of events attended by EMCDDA staff during the 
year.
Moreover, the EMCDDA organised 45 external visits to its offices in 2013, representing 
about 260 visitors. Support and visibility was given to the visits programme, including 
customised information packs and website and social media coverage (see Main area 10).
The EMCDDA marked the International Day against Drug Abuse and Illicit Trafficking (26 
June) with an event at its premises for the Lisbon diplomatic community and its partners 
An example of videos produced in 2013
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from the Portuguese authorities. The Models of Addiction Insights report was launched 
then, along with news release/social media coverage.
Building sound contacts and relations with journalists and providing media-friendly 
information continued to be a priority in 2013. During the year, 12 news releases and 13 
fact sheets were launched. Closer contacts were established with the Association of 
Foreign Press in Portugal (AIEP) and with specialist drug journalists in the Member 
States. Special focus was given to expanding media contacts in Croatia, the three Baltic 
countries and Portugal. Press events relating to the release of the EU drug markets report 
included a jointly conceived and executed launch with Europol and Commissioner 
Malmström’s press office, and the EDR package launch included a press briefing and 
press conference with a video delivery by Commissioner Malmström. Media relations 
support was also provided to the EMCDDA Scientific paper award and the third new 
drugs forum in June.
The EMCDDA continued its monthly reporting cycle on press requests and coverage via 
press activity reports and registered close to 200 (194) press requests during the year 
(compared with 166 in 2012).
Press reviews were also compiled in the wake of key events. Results relating to the EDR 
showed a total of 1 800 items of coverage (30 countries + ‘Europa’ + EU institutions + 
international). The countries with the highest coverage were Germany, Spain, France and 
Portugal. Out of this total, 584 items were recorded in the international category from 58 
countries.
The analysis also included figures on advertising value equivalent (AVE) and opportunity 
to see (OTS). These public relations industry standard measurements give an 
approximate indication of the benefit to the EMCDDA of the media coverage. The total 
AVE for all coverage on the EDR 2013 was estimated at EUR 7 460 807 and the total OTS 
at 1 017 813 503, representing substantial increases compared with the Annual report in 
2012 (AVE for 30 countries + three categories was EUR 2 287 156 and the OTS was 
EUR 187 501 022).
Another key event with impressive media coverage was the launch of the EU drug markets 
report: a strategic analysis (see Main area 4). The total number of articles related to this 
event was 435. The three countries with the largest volumes were Germany, Ireland and 
Italy with total volumes of 53, 38, and 24 respectively. Web-based media provided the 
highest number of articles, 170 (52 %).
Special focus on Croatia
The EMCDDA participated in an event for Croatian journalists in Zagreb on 16 July. This 
took place in the context of a strategy in 2013 to boost press activity with Croatia at the 
time of its accession to the EU and to expand media contacts there. A press review was 
prepared in the wake of this event.
The EMCDDA also received a visit from 23 Croatian journalists in May. The study visit, 
entitled ‘On the path of EU funds’, was funded by the Delegation of the EU to the Republic 
of Croatia. The Director’s visit to Croatia on 22 October was also promoted (see Main 
area 10).
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Supporting scientific knowledge and research (library and documentation 
services)
Tailored information was proactively distributed to EMCDDA staff, and a literature search 
was carried out to support projects. The library received 530 individual requests during 
the year. A total of 1 073 items were added to our in-house catalogue in 2013. The library 
service was embedded as an intrinsic part of EMCDDA projects. Bulletins on a range of 
topics (co-morbidity, treatment, infectious diseases and prisons) were distributed every 
two weeks, both to EMCDDA staff and to interested external users (23 bulletins on each 
topic through the year). 
Networking with other libraries and librarians to exchange experience and share best 
practices was done during the Eurolib meeting (Brussels, April) and at the meeting of the 
Science Health and Environment Cooperation area group of libraries in Ireland and via 
social media.
I  Governance, management and networks (Main area 10)
This year marked the start of the implementation of recommendations arising from the 
third external evaluation of the agency, along with tasks to enhance governance and 
management at the start of the new three-year strategy.
However, as already mentioned, 2013 was also a challenging year. The cut in the Centre’s 
subsidy for 2014 already had repercussions in 2013. The Director and his staff worked 
hard to develop a realistic plan of action in order to lessen the impact of the impending 
budget restrictions. This included a set of measures to rationalise use of human, financial 
and material resources in 2013, along with an exercise to prioritise the work planned for 
2014.
I  Main highlights from the area
Management Board — main decisions
The Management Board met twice during the year, on 4–5 July and 5–6 December.
For the first time, following Croatia’s accession to the EU on 1 July, representatives from 
this country took part in the July meeting.
At the same meeting, the Management Board gave a favourable opinion on the final 
accounts for 2012 and congratulated the Director and his staff on the best budget 
implementation results ever achieved by the agency.
The Management Board welcomed the final monitoring report linked to the 2010–12 work 
programme, which demonstrated the agency’s positive overall performance.
The Board gave the Director the mandate to negotiate a MoU between the EMCDDA and 
the National Security Council of the Republic of Armenia.
EMCDDA staff provided the Management Board members with an overview on the 
Centre’s activities on polydrug use, and with an update on scaling up the area of supply 
and supply reduction.
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The EC invited the Board members to comment the draft vacancy notice for the 
recruitment of a new EMCDDA Director, as the post of the current Director expires on 30 
April 2015, and gave details of the time schedule for the recruitment procedure.
The EMCDDA’s 2014 budget and work programme were key points on the agenda at the 
48th meeting, which took place on 5–6 December.
The Management Board gave its final seal of approval to the 2014 work programme. All 
planned activities were prioritised according to three levels, and key performance 
indicators and corresponding annual targets were defined for the areas of governance, 
administration and information and communication technology (ICT), further to the 
action plan endorsed by the Management Board in July. The EMCDDA Scientific 
Committee and the EC gave a favourable opinion on the draft work programme submitted 
by the Director.
A budget of EUR 15 183 962 (28 Member States and Norway) was adopted for 2014, on 
the basis of an EC subsidy of EUR 14 794 000. This shows a drop of EUR 1 310 000 in 
relation to the provisional budget prepared for 2014, and a cut of around EUR 756 000 in 
subsidy compared with 2013. In this context, one of the measures in the 2014 draft 
budget is a reduction of 20 % in the maximum possible co-financing available for each 
NFP.
The Board adopted a revised EMCDDA Financial Regulation, to comply with the new 
Framework Financial Regulation adopted by the EC, in view of its entry into force on 1 
January 2014, and endorsed the EMCDDA action plan further to the Internal Audit 
Service of the EC (IAS) 2013 audit on budgeting and monitoring.
The Management Board adopted the text of the MoU between the EMCDDA and Eurojust, 
and mandated the Director to sign it.
Ms Laura D’Arrigo (France) and Mr Franz Pietsch (Austria) were elected as members of 
the Executive Committee for 2014–16 inclusive. The Vice-Chair, Mr Claude Gillard 
(Belgium), was appointed as observer from the Management Board on the EC’s pre-
selection panel for the recruitment of the new Director.
The Management Board appointed 15 members of the EMCDDA Scientific Committee for 
the period 2014–16, and prepared a reserve list of 15 members.
The Management Board took note of the key elements of the agency’s staff policy plan for 
2015–17. At both meetings, the Director provided the Board members with information on 
his external activities and also reported on recent developments in cooperation with 
non-EU countries, international organisations and other EU agencies in December.
The Board finally discussed the EC’s proposal for a draft Regulation on NPS, and was also 
invited to provide input to the EC’s Communication on the future agenda for Home Affairs.
MEETINGS OF THE MANAGEMENT BOARD
4–5 July
5–6 December
Lisbon
Lisbon
47th meeting of the Board
48th meeting of the Board
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Executive Committee – main decisions
In 2013, the Executive Committee met four times (see box below).
At its May meeting, the Executive Committee commented on the draft documents 
prepared for the subsequent Management Board meeting in July. Mr Gillard informed the 
meeting that he would be representing the Chair at a meeting of Chairs and Vice-Chairs 
of EU agencies to discuss the implications of the Common Approach on EU decentralised 
agencies endorsed by the EU institutions and the consequent roadmap for agencies.
On 4 July, the Executive Committee prepared for the Management Board meeting 
starting later that day. The Budget Committee and the Executive Committee 
congratulated the Director, the accountant and the financial management team on the 
very clear accounts and the excellent level of budget execution in 2012.
At its October meeting, the Executive Committee decided, following the recommendation 
of the Budget Committee, to launch a written procedure for the adoption of the amending 
budget to the 2013 budget by the Management Board, in order to be able to reallocate 
resources without delay. The Executive Committee also commented on the documents 
for the December Management Board meeting.
The regular meeting of the Executive Committee was followed by a second meeting, 
during which the Committee established a shortlist of 15 members for the new EMCDDA 
Scientific Committee and a reserve list of 15 members, to be approved by the 
Management Board in December.
On the morning of 4 December, the Executive Committee prepared for the Management 
Board meeting starting the next day.
The Chair of the Budget Committee reported on the conclusions of the aforementioned 
committee at the start of each meeting.
MEETINGS OF THE EXECUTIVE COMMITTEE
7 May
4 July
15 October
4 December
Lisbon
Lisbon
Lisbon
Lisbon
Scientific Committee
The Scientific Committee convened for regular meetings twice during 2013 (see box 
below).
The risk assessment for 5-(2-aminopropyl)indole (5–IT) was successfully conducted by 
the Scientific Committee on 11 April, in conjunction with the Committee’s regular meeting 
(see Main area 5).
In April, special sessions were dedicated to the new EDR package and to setting priorities 
in the EMCDDA’s work programmes. The Committee also prepared a contribution to the 
HDG’s annual dialogue on research, based on the EMCDDA’s gap analysis on evidence 
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available for treatment effectiveness and research priorities (see Main areas 3 and 7). In 
November, the Committee had an in-depth discussion with the scientific staff on the draft 
2014 work programme before adopting their formal opinion on it.
The Scientific Committee also made a significant contribution to the EMCDDA Scientific 
paper award (see Main area 7).
Scientific Committee members peer-reviewed the following EMCDDA publications: the 
Trends and developments report (EDR); Drug policy advocacy organisations in Europe 
(EMCDDA Paper, December release); Treatment of cannabis-related disorders (Insights); 
the Drug policy profiles of Poland and Austria; and a Paper on intergovernmental 
(regional) drug strategies (the last four will be 2014 releases).
The mandate of the Scientific Committee members came to an end in December 2013. A 
call for expressions of interest for members was published in the Official Journal of the 
EU and on the EMCDDA website on 22 January. In total, the agency received 79 
applications from 63 candidates. Following a pre-selection panel meeting, the Executive 
Committee met in mid-October to assess the panel’s proposal and agreed with its 
shortlist of 15 candidates and reserve list of 15 candidates.
At its December meeting, the Management Board appointed the new Scientific 
Committee members and established a reserve list.
MEETINGS OF THE MANAGEMENT BOARD
11–12 April
7–8 November
Lisbon
Lisbon
38th meeting of the Committee
39th meeting of the Committee
External evaluation of the EMCDDA
The third external evaluation of the EMCDDA was finalised in 2012. This resulted in 15 
recommendations. An action plan to follow up these recommendations was prepared by 
the Centre and endorsed by the Management Board in July 2012. It defined the measures 
to be taken during the implementation of the 2013–15 work programme.
The Centre carried out an internal assessment to measure the progress achieved after the 
first year of implementation of the triennial work programme. On the whole, the exercise 
showed positive progress in implementing the 15 recommendations (for details see 
Annex 8 online). A key performance indicator (KPI) was included in the 2014 work 
programme (45) in order to measure the implementation of the follow-up action plan.
EMCDDA Director — Main activities in 2013
Management in the agency was the responsibility of the Director supported by his team of 
managers. Regular Heads of unit meetings were organised throughout the year (10 in 
2013). These meetings are the agency’s main managerial forum, addressing both 
strategic and operational issues. In addition, the Coordination group met 17 times to 
support the Heads of unit meetings.
(45) Available at emcdda.europa.eu/publications/work-programmes/2014
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In addition, through his activities, the 
Director helped increase the visibility of the 
Centre and consolidate the credibility of its 
work, by building and strengthening 
partnerships.
EU institutions
A key moment in the EMCDDA’s relations 
with the EC in 2013 was the launch of the EU 
drug markets report: a strategic analysis in 
Brussels on 31 January at a press 
conference together with Commissioner 
Malmström and the Director of Europol, Rob 
Wainwright. The Director of the EMCDDA 
also presented the report to the LIBE 
Committee of the EP in Brussels on 20 
February. He subsequently presented the EMCDDA’s 2013 EDR to the international press 
at the EMCDDA headquarters on 28 May and to the LIBE Committee on 30 May. The EDR 
was then presented to a JHA Ministers meeting at the Council of the EU in June. In July, 
Mr Götz welcomed a delegation of Members of the European Parliament (MEPs) from the 
LIBE Committee to the EMCDDA’s offices.
The Director also had several meetings in Brussels with EC representatives, including Ms 
Lotte Knudsen, Director of the Criminal Justice Directorate in DG Justice, Mr Reinhard 
Priebe, Director of the Internal Security Directorate in DG Home Affairs, and other 
officials.
The Director welcomed Mr Fredrik Ekfeldt from the EU Intelligence Analysis Centre of the 
European External Action Service to the EMCDDA’s offices in Lisbon.
On the margins of the Assembly of Agency Staff Committees meeting, the Director had a 
meeting with Mr Frutuoso de Melo, Deputy Director-General, DG Human Resources and 
Security, and with the Executive Director of EMSA.
In the framework of audit visits to the Centre, Mr Götz met with representatives of the 
European Court of Auditors and the Internal Audit Service.
The EMCDDA organised the 33rd meeting of the Data Protection Officers, which ran from 
28 February to 1 March, and the European Data Protection Supervisor and the Director 
made a welcoming address at the event.
EU agencies
Regarding relations with the other EU agencies, the Director attended the two Heads of 
agencies network meetings held in Brussels, and the meeting organised by the European 
Railway Agency in Valenciennes.
Mr Götz also participated in the third informal strategy meeting of Home Affairs agencies, 
organised by CEPOL in Bér Nógrád (Hungary), and a meeting of the JHA group of 
agencies organised by the same agency in Bramshill (UK).
Francisco Cumsille, Coordinator of the Inter-American 
Drugs Observatory, Ambassador Paul E. Simons, 
Executive Secretary of CICAD-OAS, Wolfgang Götz, 
EMCDDA Director, and Alexis Goosdeel, Head of the 
Reitox and international cooperation unit during 
CICAD’s visit on 6 November
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In addition to his regular meetings with the EMSA Director, Mr Götz met with the 
Executive Directors of EMSA and the European Fisheries Control Agency with the specific 
aim of exploring areas for further inter-agency synergy.
Relations with EU Member States
In January, the Director attended the presentation of the external evaluation of the 
Portuguese national plan to combat drugs, organised by SICAD (Serviço de Intervenção 
nos Comportamentos Aditivos e nas Dependências — General Directorate for 
Intervention on Addictive behaviours and Dependencies). Later in the year, he also took 
part in SICAD’s first Congress, held in Vimeiro.
In Lisbon, Mr Götz attended two ceremonies linked to the environment directly 
surrounding the EMCDDA’s offices. The main event was the renaming of the square in 
which the agency’s office is located (Praça Europa), in the presence of Lisbon’s Mayor, Mr 
António Costa, and the President of the European Parliament, Mr Martin Schulz, who then 
met with Mr Götz. The Director also attended the official ceremonies to celebrate the 
Portuguese national day on 10 June, presided over by Mr Aníbal Cavaco Silva, the 
Portuguese President.
On 22 January, Mr Götz signed a MoU between the EMCDDA and the First Faculty of 
Medicine of Charles University, Prague. The first outcome of this MoU was the 
organisation of a Reitox Academy training course for IPA 4 beneficiaries in April.
In February, the Director welcomed a high-level delegation from Croatia to the EMCDDA, 
including two members of the Croatian Parliament, the Director of the Office for 
Combating Drug Abuse of the Government of the Republic of Croatia and other senior 
officials. Director Götz also attended the workshop on the National Drugs Monitoring 
System in Zadar in October.
In March, a delegation from the German Federal Intelligence Service visited the Director.
Mr Götz met with several ambassadors and their delegations during the year, including Mr 
Hans Michael Kofoed-Hansen, Ambassador of Denmark, and Mr Lars Rasmussen, 
Spokesperson of the Municipality of Copenhagen responsible for Social Affairs; Mr 
Helmut Elfenkämper, Ambassador of Germany; Ms Nathalie Auvray, Attaché for Internal 
Security, and Mr Daniel dos Santos, Senior police officer responsible for organised crime 
and drug trafficking from the French embassy; and the Greek Ambassador Mr Panos 
Kalogeropoulos. Throughout the year, he also had bilateral meetings with ambassadors of 
other EU Member States and attended a number of receptions held to mark national days 
at the embassies of EU Member States.
As in previous years, on 26 June the Director welcomed the ambassadors in Lisbon as 
well as representatives of the Portuguese authorities to a reception at the EMCDDA’s 
premises to mark the International Day against Drug Abuse and Illicit Trafficking.
Relations with non-EU countries
In January, the Director received a visit from the Swiss Ambassador to Portugal, and in 
March he received a visit from Mr Ehud Gol, Ambassador of Israel, and Mr Lior Keinan, 
Councillor at the embassy. The main topic for discussion was the preparation of the MoU 
between the EMCDDA and the Israel Anti-Drug Authority. In September, Mr Götz welcomed 
Israel’s new Ambassador to Portugal, Ms Tzipora Rimon, to the EMCDDA’s offices.
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On the margins of the Reitox week in May, Mr Götz met with three representatives from 
the National Security Council of the Republic of Armenia (Mr Arthur Baghdasaryan, Mr 
Artashes Avoyan and Mr Varuzhan Bolorchyan) to discuss further cooperation between 
the National Security Council and the EMCDDA.
Ambassador Paul E. Simons, Executive Secretary of CICAD, met with the Director in 
November during his visit to Portugal.
Other organisations and bodies
Mr Götz received the outgoing and incoming Directors of MAOC-N (the Maritime Analysis 
and Operations Centre — Narcotics), Mr José Ferreira Leite and Mr Frank Francis 
respectively, in October. He further met with the new Director of MAOC-N in November 
and December.
The Director addressed the participants of the First international congress on drugs and 
drug addiction, organised by the ‘Instituto Superior de Ciências Educativas’ (ISCE) and the 
Centre for Drug Misuse Research Scotland, which took place in Lisbon from 23 to 25 May.
Data protection activities
Implementation of data protection activities continued throughout the year, in order to 
ensure compliance with the rules applicable to EU bodies (Regulation (EC) 45/2001). 
Issues addressed included: future guidelines on e-communications; business continuity 
plan; appraisal and training processes; public procurement, external experts and grants; 
and auditors’ access to personal data.
The 33rd meeting of the Data Protection Officers and the European Data Protection 
Supervisor took place at the EMCDDA and was attended by 58 participants from EU 
institutions, agencies and other EU bodies.
Collaboration with the host Member State
The EMCDDA pays particular attention to its relations with its host country, Portugal. In 
2013, the Centre maintained regular 
contacts with the Ministry of Foreign Affairs 
and the Municipality of Lisbon. As already 
mentioned, one key event was the 
inauguration by the President of the 
European Parliament, Martin Schulz, and the 
Mayor of Lisbon, António Costa, of Praça 
Europa, the square where the EMCDDA and 
EMSA are located.
Collaboration with Croatia, new 
Member State
Another major development during the year 
was the enlargement of the EU with a new 
Member State, Croatia, from 1 July. A few 
days later, at the Management Board 
Wolfgang Götz, EMCDDA Director, Martin Schulz, 
President of the European Parliament, António Costa, 
Mayor of Lisbon and Markku Mylly, Executive Director 
of the European Maritime Safety Agency, during the 
inauguration of Praça Europa in Lisbon [Photo 
courtesy of the Câmara Municipal de Lisboa]
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meeting, the Chair welcomed the representatives from Croatia to the Board, and 
presented the highlights of cooperation between Croatia and the EMCDDA. In October, 
the Director made his first official visit to Croatia, opening a workshop organised by TAIEX, 
in cooperation with the EMCDDA and the Office for Combating Drug Abuse of the 
Government of the Republic of Croatia, in Zadar. The aim of the workshop was to 
showcase Croatia’s achievements to date in developing its national drug information 
system and to increase the visibility of the EMCDDA and the NFP in the country.
External visitors
In 2013, EMCDDA staff coordinated or organised 45 visits by external parties, involving 
260 visitors.
Interest in the EMCDDA’s activities continues to grow steadily. The EMCDDA’s work is 
relevant for a variety of target groups, including policymakers, scientists and researchers, 
practitioners and European citizens.
Some visits aimed to improve the visitors’ understanding of the EMCDDA’s mandate and 
activities. Such groups included law students and representatives of the Dutch United 
Nations Student Association, journalists from Croatia, pharmacists from France, German 
police officers, scholarship holders from the Hanns Seidel Foundation of Munich and 
students from the Faculty of Pharmacy of the University of Lisbon.
Other visits focused more on discussing possible cooperation and an exchange of 
technical knowledge. High-level representatives from international organisations, such as 
the Executive Secretary of CICAD–OAS, the National Secretary for Drug Policies of Brazil 
and the General coordinator of the Brazilian Monitoring Centre on Drugs, all visited the 
agency. In the same vein, the Home Office Minister for Crime Prevention from the United 
Kingdom visited the EMCDDA as part of a reassessment of the UK’s policy on drugs and 
drug addiction.
Among third countries, we should mention visits by a group of university students from 
the Addiction Programme of the Public Health Department of Syracuse University (USA), 
a delegation from the Turkish Ministry of Family and Social Policies, a delegation of 
researchers and writers from Japan and the visit of the Deputy Mayor of Rio de Janeiro.
Strategic planning, monitoring and reporting
The General Report of Activities 2012 (46) was published online on 14 June, as required by 
the agency’s recast Regulation. The report was substantially improved, including a new 
annex (Annex 5) on the detailed implementation of the 2012 work programme. This helps 
increase the Centre’s transparency and accountability towards its external stakeholders. 
Furthermore, the report was presented in a new layout, in line with the refreshed 
corporate identity launched in 2013.
The final monitoring report for the EMCDDA´s 2010–12 strategy and work programme was 
presented to the Management Board at its July meeting. The report showed that the 
EMCDDA performed well during the period. Out of the 15 objectives defined by the 
(46) Available at emcdda.europa.eu/publications/general-report-of-activities/2012
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documents concerned, 12 were fully achieved (80 %) (47) and three were partly achieved. 
In addition, 104 publications were released and 90 scientific articles were published.
The 2014 work programme adopted by the Management Board in December (48) gives, for 
the first time, priority levels to activities and defines, also for the first time, KPIs for three 
main areas: governance, management and networks (Main area 10); administration: 
supporting core business (Main area 11); and ICT (Main area 12).
Internal control systems and risk management
In order to improve financial management, financial circuits were clearly defined, along 
with the roles and duties of the staff members involved. This included authorisations to 
access the ABAC system, including back-up arrangements. Manuals of procedures, 
including checklists, were adopted and implemented. Exceptions relating to non-
compliance with the Financial Regulation rules were recorded centrally. Deadlines for 
making payments were respected and recommendations arising from audits were duly 
implemented (see also Part II — Management and internal control systems).
Reitox network
The second Reitox week was held in May 2013 and the first two days of the meeting were 
open to IPA and ENP countries (see Main area 8) to encourage a broad exchange of 
experience. In total, representatives from over 40 countries attended the event. The last 
two days were dedicated to the HFP meeting.
The next HFP meeting took place in November. It focused on the EMCDDA’s 2014 work 
programme and the proposal to review the national reporting system.
The revision of the national reporting system is part of the action plan to implement the 
systemic review of tools started in 2011 (see Main areas 1 and 7). The revision also needs 
to respond to the diminishing resources available at reporting country level and the cut in 
human and financial resources experienced by the EMCDDA. This was a critical concern 
in 2013, following the already mentioned unexpected drop in the EU subsidy to the 
EMCDDA for 2014, which will impact on the co-financing of NFPs.
In view of this difficult reality, the NFPs welcomed the proposal for a new Reitox national 
reporting system, which should allow the Centre and the NFPs to better address the 
information needs of European and national stakeholders alike while rationalising 
resources.
Following a project started in 2012 to enhance the organisational capacity of NFPs, a 
technical meeting took place in March with six volunteer NFPs. Based on the outcomes of 
the meeting, a roadmap for implementing the project was prepared and discussed at the 
HFP meeting in May. The project will continue in 2014, in line with available resources.
(47)  This analysis reflects the proportion of objectives achieved out of the total number of objectives defined in the 
EMCDDA 2010–12 work programme. It does not reflect the weight of different objectives to the overall 
achievement status, which requires a more in-depth, qualitative assessment.
(48) Available at emcdda.europa.eu/publications/work-programmes/2014
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MEETINGS OF THE REITOX NETWORK
21–24 May
23–24 May
27–29 November
Lisbon
Lisbon
Lisbon
Second Reitox week
48th Reitox meeting of heads of focal points
49th Reitox meeting of heads of focal points
On-site institutional support was provided to six countries (upon request), in order to 
improve their data collection and reporting. Specific training on grant management was 
provided to Croatia, to help prepare the country for submitting its first grant request to the 
EMCDDA.
In addition, four Reitox Academies were organised during the year: one on Fonte Training 
XML (including a presentation of the new Template for TDI) to enhance the skills of 10 
NFPs in using XML for reporting data; a Regional Academy for Baltic countries on 
monitoring trends and responses in relation to drug-related infectious diseases among 
people who inject drugs, attended by 16 participants and NFP experts from four Member 
States; a National Academy on ‘Best practices in prevention’ organised by the Maltese 
NFP and attended by 23 experts; and a National Academy on innovative approaches in 
harm reduction, organised by the Austrian NFP (see Main area 3), the 22 participants in 
which were provided with the most recent information on best practices in provision of 
naloxone to prevent drug-related deaths and on how to promote opioid substitution 
treatment through low-threshold services.
I  Administration: supporting core business (Main area 11)
One of the main commitments in the EMCDDA’s 2013–15 work programme is to increase 
efficiency and maximise value from activities and investments. Administration tasks at 
the EMCDDA contribute significantly to meeting this goal, whilst providing high-quality 
services to core business.
I  Main highlights and achievements from the area
Financial management
EMCDDA procedures, manuals and templates were revised in order to meet the 
requirements of the revised general EU Financial Regulation which entered into force on 1 
January 2013, and financial staff members were trained in how to implement the new 
rules.
The Financial Regulation applicable to the EMCDDA was also revised and the document 
was adopted by the Management Board on 5 December.
Further measures to improve budget implementation and the use of resources were in 
place. As a result, an outstanding budget execution rate was achieved (see below), 
consolidating the levels obtained in 2012. In addition, tendering procedures were further 
rationalised, leading to a reduction of 5 % in negotiated procedures with a single tender 
and a 24 % increase in order forms related to framework contracts. The average time for 
making payments was also reduced.
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TENDERING 2013 figures
Negotiated procedures — disp. Art. 126 (exceptional procedures) 0
Negotiated procedures — single tender 172
Negotiated procedure — at least three candidates 4
Open procedures 5
EC framework contracts joined 2
New framework contracts launched 3
Order forms related to framework contracts 114
Budget and accounting (including budget planning, monitoring and 
reporting)49
As previously mentioned, the EMCCDA once again achieved an outstandingly efficient 
management of its budget (execution rate) in 2013, as follows:
Commitments 99.74 %
Payments made 97.71 %
Consumption of 2012 (C8) credits (49) 95.14 %
As in 2012, this was possible only because of the efforts of all staff involved, across all 
core business and support areas. It was also thanks to the improved budget management 
practices applied during the year.
In addition, the 2014 budget and a preliminary budget for 2015 were adopted by the 
EMCDDA Management Board.
Human resources
Major tasks for this sector in 2013 were preparing the EMCDDA’s human resources 
processes and policies for the revised EU Staff Regulations, due to enter into force on 1 
January 2014. Actions focused on the revision of pecuniary rights and entitlements, along 
with new recruitment templates.
In addition, the EMCDDA contributed actively to discussions concerning the new Staff 
Regulations held between the EC (DG human resources) and the EU agencies.
A follow-up action plan to the staff opinion survey carried out in 2012 was further 
developed and implementation of two interventions got under way.
A prevailing objective in 2013 was to further develop the EMCDDA’s working and output 
capacity by maximising training opportunities for staff. Individual training plans were set 
during the annual staff performance appraisal exercise and training was delivered in line 
with available resources. The total number of training days increased by 25 % from 2012 
figures (see table below).
(49) C8 credits: open commitments carried forward from the previous year.
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TRAINING PROVIDED IN 2013
Total number of training days 422
Training courses per staff member (average) 2.5
Training days per staff member (average) 4.1
Infrastructure and logistics
The EMCDDA’s business continuity plan (BCP) was developed and approved by the 
Director. The document identifies the organisation’s critical work processes, business 
functions, assets and records and how they relate to the EMCDDA’s mission. The BCP 
also identifies crisis coordination structures, naming key personnel and deputies, their 
roles and responsibilities, for different types of crises. The document will be reviewed 
each year, and revised when needed.
A proposal for an environmental management system was also developed and approved 
by the Director. A draft implementing policy was prepared and will be applied from 2014. 
No work-related accidents were reported in 2013.
In order to be more efficient and save money, the Centre identified a number of areas for 
exploring synergies with EMSA (see Main area 8).
I  Information and communication technology (ICT)  (Main area 12)
Information and communication technology programmes and services support the 
agency’s core objectives and guarantee the smooth operation of all services. In times of 
rapid technological development and increasing expectations from both external and 
internal stakeholders, developing ICT governance is central to helping the agency 
implement its work programme and achieve its mission.
Three overarching priorities were identified for the ICT area in the 2013–15 work 
programme and they guided the work in 2013: to develop and maintain instruments for 
supporting core business; to implement a ‘business and information architecture 
management’ programme; and to implement a ‘technical services management’ 
programme, including ongoing service management.
I  Main highlights and achievements from the area
Fonte, the EMCDDA’s web-based data collection instrument, and the Drugs Data 
Warehouse are the main applications supporting the agency’s data collection, validation 
and analysis. Most of the work in the ICT area was dedicated to maintaining and adjusting 
these to the needs of the 2013 work programme.
New instruments and support were provided to the Internet ‘snapshot’ in February 2013 
and work started to define the new EDND. However, progress in this area depends on 
resources and the entry into force of the new legal framework replacing Council Decision 
2005/387/JHA (see Main area 5).
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Another priority for the EMCDDA which requires strong support from the ICT area is 
website development. In 2013, a roadmap was developed to support the new web content 
management and visualisation platform, identifying requirements of the new system. A 
tender was completed and a service contract signed (see also Main area 9).
The role of the ICT Steering Committee in defining priorities in this area was enhanced. 
This was particularly important in 2013 in relation to the cut in the Centre’s subsidy for 
2014. Therefore, a thorough prioritisation and rationalisation of work for 2014 took place 
and the two top levels of priority for 2014 were set at the second Steering Committee 
meeting in December.
The infrastructure of the office’s technical material was developed according to plan. This 
included acquiring corporate servers and upgrading Office 2010 applications on all 
machines.
The implementation of the project management methodology approved by the ICT 
Steering Committee in 2012 continued and 70 % of the active projects were managed 
accordingly.
II
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PART II 
Management and internal 
control systems: 
annual activity report as per the 
Financial Regulation applicable 
to the EMCDDA
CHAPTER 5 
Characteristics and nature of EMCDDA 
management and internal control systems
CHAPTER 6 
Assessment and improvement of 
management and internal control systems
CHAPTER 7 
Declaration of assurance by Authorising Officer 
and Management Board’s analysis and 
assessment of the Authorising Officer’s General 
Report of Activities for the financial year 2013
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In accordance with the Financial Regulation applicable to the EMCDDA, which includes 
the text of the EC’s Framework Financial Regulation No 2343/2002 (50), the EMCDDA has 
set its internal procedures for budget execution and internal control, while defining and 
implementing a partially decentralised management model.
As a consequence, both operational and financial decisions required for the 
implementation of the EMCDDA’s work programme and budget have been delegated to 
the Heads of unit/Head of scientific division. The Administration unit provides support to 
managers for budgetary and financial management and execution, as well as for overall 
internal planning and monitoring.
These procedures have been codified and all of the EMCDDA’s deputy authorising officers 
have received specific training and information on their role, duties and liability, in 
accordance with the provisions of the financial and staff regulations.
The key actors and steps of the EMCDDA procedures for budget execution can be 
summarised as follows:
•  Project manager: initiative and operational input for administrative and financial 
operations related to project implementation (technical specifications for tendering 
procedures, cost estimate, ‘certified correct’ for payments);
•  Financial management team: financial and contractual support officers help prepare the 
administrative and contracting supporting documents with the project manager concerned;
•  Budget planning and monitoring team: checks consistency with work programme and 
budget allocations;
•  Financial management team: initiating officers carry out operations in the EMCDDA’s 
ABAC electronic management and accounting system, prior to the decision of the 
Authorising Officer;
•  Directorate: the verifying officer carries out ex ante checks;
•  Head of unit/Head of scientific division: gives authorisation of budgetary and legal 
operations, acting as deputy authorising officer by delegation (from the Director as 
EMCDDA authorising officer) for the execution of the tasks/activities of his/her unit, 
within the limits of the adopted EMCDDA annual work programme and budget;
•  Accountant: makes the required financial transactions.
(50) As last amended by Commission Regulation (EC, EURATOM) No 652/2008.
CHAPTER 5
Characteristics and nature of 
EMCDDA management and 
internal control systems
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The procedures presented above are consistent with the EMCDDA’s project-based 
working methods and in accordance with activity-based management/activity-based 
budgeting principles. In this context, the EMCDDA has established procedures for 
planning, monitoring and reporting, with a clear indication of the actors involved and their 
roles and responsibilities.
Following the adoption of the new ‘Operating framework for the Reitox system’ in January 
2003, a new grant agreement model was introduced for the annual co-financing of 
activities by the Reitox NFPs. This agreement requires an external audit each year by an 
independent body or expert in order to certify that the financial documents submitted to 
the EMCDDA comply with the financial provisions of the agreement, that the costs 
declared are the actual costs, and that all receipts have been declared.
The EMCDDA is currently subject to the following checks and controls:
•  External audit by the European Court of Auditors (twice a year);
•  Discharge by the European Parliament (once a year);
•  Assessment and adoption of the General Report of Activities; opinions on annual final 
accounts; adoption of annual and three-year work programmes by the EMCDDA’s 
Management Board;
•  Internal audit by the EC’s Internal Audit Service (once a year);
•  Opinion of the EC’s services on the agency’s staff policy plan (once a year);
•  Periodical external evaluation (every six years);
•  Agreement by the EC on implementing rules to staff regulations (for each rule);
•  Consent by the EC on possible deviation of EMCDDA Financial Regulation from the 
EC’s Framework Financial Regulation for decentralised agencies;
•  The European Data Protection Supervisor for compliance with Regulation 45/2001 (by 
prior notification and upon complaint);
•  The European Anti-Fraud Office (upon complaint);
•  The Ombudsman (upon complaint); and
•  The Civil Service Tribunal — Court of First Instance — European Court of Justice (upon 
complaint).
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CHAPTER 6
Assessment and improvement 
of management and internal 
control systems
I  Key features of the EMCDDA’s partially decentralised management model
Actors/level of operations Role/operations
Decentralised level (operational 
and technical units)
Operational initiative/input and operational and financial 
decisions by delegation in order to implement the work 
programme and budget
Central level (Directorate and 
Administration unit)
Coordination and management of executive planning, 
monitoring, reporting and assessment of the 
implementation of the work programme and budget
Administrative and financial support, management and 
control of implementation
Key actors and processes for the execution of the EMCDDA work programme and 
budget
Level of operations Actors Role/operations
Decentralised level 
(operational and 
technical units)
Project manager and 
Head of unit/Head of 
scientific division 
concerned 
Initiative and operational input for the 
operations required to implement projects 
Central level 
(Administration unit)
Budget planning and 
monitoring team
Checks operations adhere to adopted work 
programme and budget. Budgetary 
appropriations to be committed are set 
aside
Human resources 
management team
Defines rights and checks compliance with 
staff regulations for staff-related 
management and expenditure 
Financial management 
team
Prepares the required administrative and 
legal supporting documents and checks 
compliance with applicable regulations. 
Processes the required ABAC operations
Central level 
(Directorate)
Verifying officer Ex ante verification
Decentralised level 
(operational and 
technical units)
Head of unit/deputy 
authorising officer 
Authorises budgetary and legal 
commitments and payments
Central level 
(Administration unit)
Accounting officer
Executes and records payments and 
recovery orders
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In 2013, following the observations and recommendations expressed by the European 
Court of Auditors and the EU Budget Authority and audits by the IAS, the EMCCDA 
implemented various measures to improve its management and internal control systems, 
as follows.
I  Measures taken in the light of the observations and comments accompanying the Decision on the discharge for 2011
I Budget and financial management/premises
Following comments received on the 2011 discharge, the agency continued to explore 
options for renting or selling our former premises. This gave rise to two consultations with 
the EU Budget Authority (both positive) in 2013, but no concrete outcomes by the end of 
that year. Work continued with the Portuguese authorities to support our endeavours to 
sell/rent the property. In the meantime, the Centre further reduced the costs linked to the 
building concerned.
I Performance
Following the third external evaluation of the EMCDDA, the Centre prepared an action 
plan to follow-up the 15 recommendations contained in the evaluation report. These 
measures are included in the new three-year work programme. The 2014 work programme 
contains a specific KPI to monitor the implementation of the action plan. An internal 
monitoring tool has been developed by the EMCDDA in order to follow the actions 
implemented within each annual work programme over the 2013–15 period.
The actions prepared and implemented in 2013 were recorded using this tool (see Annex 
8: Follow-up action plan to the third external evaluation of the EMCDDA). Pursuant to the 
relevant provisions, this General Report of Activities will be submitted for analysis and 
adoption by the Management Board by mid-May 2014, and forwarded to the EP, the 
Council, the Commission and the Court of Auditors by 15 June 2014.
I Carryover appropriations
Following the measures put in place to reduce appropriations carried forward (see 2012 
General Report of Activities), the amount carried forward from 2012 to 2013 amounted to 
EUR 222 758. This represents a drop of 16 % from the figures for 2011 to 2012.
I Treasury policy
Further to measures already in place to reduce risk in this area, namely for the 
procurement of banking services, the EMCDDA has a policy in place that periodically 
monitors changes in the situation.
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I Policy on exceptions
Further to procedures already in place for managing exceptions, the Centre has revised 
its policy to cover any exception that reflects a deviation from any rule formally adopted 
and in force in the EMCDDA.
I Recruitment procedures
The EMCDDA has adjusted its recruitment processes to allow for an earlier definition of 
the content of written tests and interviews (i.e. before the selection board analyses the 
applications received), taking into account the relative risks at stake and the actual costs 
and benefits involved.
I Internal audit
The agency has implemented four out of the six ‘important’ recommendations made by 
the IAS in its 2011 audit, and these are closed. Two remain: one on the setting up of a 
performance monitoring system including KPIs and the other on the assignment of 
responsibilities to check recommendations made in ex post control reports. 
Implementation of the KPIs started in 2013 and will be completed in 2015, covering all of 
the EMCDDA’s activities. The verification of the recommendations resulting from ex post 
controls will be implemented, where applicable.
I  Measures taken in the light of the observations and recommendations expressed by the European Court of Auditors
The EMCDDA now implements several processes to ensure adequate ex ante and ex post 
checks regarding grant management, taking into account the risks at stake. Grant 
beneficiaries are asked to send a full statement of expenses, along with final financial and 
activity reports, so that the EMCDDA can check the eligibility and accuracy of the costs 
claimed. The agency then draws up bilateral feedback reports relating to the 
administrative management of the Reitox grants and analyses them with the NFPs.
In order to further improve the system, the EMCDDA has taken the following measures, in 
line with the Court’s suggestions:
•  increased the number of annual on-site checks in NFPs;
•  made available an audit methodology and improved model for the external audit report, 
to facilitate, as much as possible, the application of a common and consistent 
methodology for external auditors’ verification;
•  organised a special session on grant management for all NFPs in May 2013.
Pursuant to the assessment of possible risks involved, the EMCDDA has revised its 
decision concerning ex post verifications, to link the latter to the results of risk 
assessment.
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Further to the measures taken to ensure business continuity and disaster recovery for 
critical ICT-based processes, the EMCDDA Director validated the BCP on 29 September. 
This document contains disaster recovery plans related to various scenarios and identifies 
available back-up sites.
The EMCDDA is still actively trying to sell or lease the unused office space in its former 
building and next to its new headquarters. The EMCDDA consulted the EU Budget 
Authority twice in 2013 with proposed solutions. Although no objection was raised to the 
solutions, neither led to concrete actions. The EMCDDA continues to pursue its contacts 
with the Portuguese authorities in relation to the selling/rental of the building. The 
German embassy contacted the EMCDDA regarding a possible rental of the Relogio 
building, while the Centre has offered to rent the former head office (Mascarenhas 
building) to MAOC-N. Negotiations in both cases are ongoing. In 2013, 32 interested 
parties visited the Mascarenhas building.
Meanwhile the EMCDDA has further rationalised and reduced the running costs for the 
Mascarenhas building, representing total savings of EUR 42 858.06 in 2013, by reducing 
services on-site and working more closely with our sister agency, EMSA.
I  Measures taken in the light of the observations and recommendations expressed by the Internal Audit Service of the EC
Following the adoption in 2013 of the EMCDDA’s BCP, the internal auditor recommended 
closing two out the three IAS recommendations from the 2008 audit. In the case of the 
remaining recommendation (‘precaution against damage from floods’), responsibility lies 
with the EMCDDA’s landlord. However, the agency has already taken out specific 
insurance to cover any possible damage resulting from floods.
In relation to the IAS recommendations from the 2011 audit, the internal auditor closed 
two of the four recommendations still outstanding at the end of 2012. Details on the 
remaining two recommendations still outstanding have been provided under ‘internal 
audit’ in the section on the 2011 discharge and will not be repeated here.
In February 2013, the IAS carried out an audit focusing on budget and monitoring which 
gave rise to three main recommendations.
1.  Procurement procedures for non-administrative activities should be based on a 
financing decision by including in future work programmes indications on the global 
budgetary envelopes for the procurement for the year concerned, the indicative 
number and type of contracts envisaged and an indicative timeframe for the 
procurement procedures.
2.  A comprehensive description of the budget preparation process should be prepared 
and all relevant documentation kept in a central file. Moreover, a sound methodology 
for the preparation of the activity-based budget (ABB) should be created and duly 
documented.
3.  Expected outputs and results indicated in the annual work programmes should always 
be specific, measurable and better timed by setting priorities.
The EMCDDA will implement the first recommendation where applicable. The number of 
contracts linked to operations awarded following a call for tender published in the EU 
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Official Journal has been, and probably will remain, very low. The main body of 
documentation relating to budget preparation procedures already exists, in relation to 
recommendation 2. Nonetheless, the EMCDDA will continue to seek further 
improvements in this field, including regarding ABB-related aspects. The final 
recommendation was already implemented by the adoption of the 2014 work programme.
I  Measures taken in order to improve the risk assessment and management system as a whole
As in previous years, a comprehensive risk identification and assessment exercise to 
improve risk management continued in 2013. The central risk register was updated, along 
with the risk register in the ICT unit. Risk analysis is a continuous exercise at the 
EMCDDA: when work programmes are in the process of being prepared, managers carry 
out more systematic reviews.
In early 2013, a comprehensive document on the state of implementation of the Centre’s 
Internal Control Standards (ICS) was completed and approved. This helped identify three 
main areas where improvement is needed in terms of the ICS (by order of priority): 
business continuity (ICS 10); governance in ICT, notably concerning project management 
(one key feature under ICS 7 — operational structures); and monitoring of performance, 
supported by KPIs (ICS 5). The EMCDDA continues to take mitigating measures to deal 
with the risks related to these.
The main improvement as regards compliance with the EMCDDA’s ICS has been the 
approval of a fully-fledged BCP for the agency: without prejudice to future improvements, 
the plan is already comprehensive enough to allow the EMCDDA to act swiftly and to 
operate recoveries in the event of an emergency or disaster.
Continuing action taken in the ICT sector is also worth mentioning, since it covered both 
governance and technical issues. Business continuity was ensured without major 
incidents, in the framework of sound procurement procedures, adequate licensing and 
proper testing of applications. In articulation with the IT sector risk register, an adequate 
risk management plan has been applied: for each area, it identifies the estimated risk 
level, the controls to be put in place and the list of ongoing programmes and projects that 
will contribute to risk reduction activities.
We are currently developing a performance-monitoring tool that plans and monitors 
activities in the work programme. The 2014 work programme has targeted the design and 
testing of such a tool. Compliance with this goal hinges on having the necessary 
resources available.
The work of the Coordination Group in 2013 also strengthened risk management 
procedures by enabling the Heads of unit and other key staff to closely monitor the 
implementation of core activities, the timely achievement of results and delivery of 
outputs.
In respect of risks associated with operations, the unauthorised dissemination of 
EMCDDA products by a private firm, witnessed in previous years, stopped. No other risks 
associated with operations materialised in 2013.
7
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I, the undersigned, Director of the European Monitoring Centre on Drugs and Drugs 
Addiction
In my capacity as Authorising Officer
Declare that the information contained in this report gives a true and fair view (1).
State that I have reasonable assurance that the resources assigned to the activities 
described in this report have been used for their intended purpose and in accordance 
with the principles of sound financial management, and that the control procedures put in 
place give the necessary guarantees concerning the legality and regularity of the 
underlying transactions.
This reasonable assurance is based on my own judgement and on the information at my 
disposal, such as the results of the self-assessment, the observations of the Internal Audit 
Service and the lessons learnt from the reports of the Court of Auditors for years prior to 
the year of this declaration.
Confirm that I am not aware of anything not reported here which could harm the interests 
of the institution.
Done in Lisbon on 26 May 2014
Wolfgang Götz 
Director
(1) True and fair in this context means a reliable, complete and correct view on the state of affairs in the service.
CHAPTER 7
Declaration of assurance 
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I  Management Board’s analysis and assessment of the Authorising Officer’s (Director’s) General Report of Activities for the financial year 2013
The Management Board has analysed and assessed the Authorising Officer’s (Director’s) 
General Report of Activities for the financial year 2013.
The Management Board appreciates the results achieved by the Centre and notes in 
particular the following.
On the content of the report:
The EMCDDA made significant progress in the implementation of its work programme for 
most planned activities. Of particular note are the achievements in the following areas.
•  Data collection, analysis and quality assurance: in May 2013, the EMCDDA presented 
its annual overview of the European drug situation in a new, reshaped information 
package — the European Drug Report (EDR), which replaced the Annual report on the 
state of the drugs problem in Europe. In addition, further steps were made to improve 
the performance of the reporting system, by launching the review of the national 
reporting package and introducing a stronger quality assurance framework for 
processes and statistical procedures.
•  Key epidemiological indicators: focus in 2013 was placed on enhancing analysis and 
network development, while methodological work was also carried out to underpin this 
core area of the EMCDDA´s business. A new approach was tested for the key 
epidemiological indicators’ annual expert meetings, to allow for more cross-indicator 
analysis, a better integration of responses and identification of trends. In January 2013, 
the EMCDDA became the host for the coordination of the European School Survey 
Project on Alcohol and Other Drugs (ESPAD).
•  Demand reduction responses: health and social responses profiles were launched as 
part of the EDR package, along with six other outputs. Implementation of the new 
treatment strategy started, and the EMCDDA week-long set of meetings on ‘Measuring, 
understanding and responding to drug problems in Europe’ took place. This was the 
agency’s first treatment-related meeting since the adoption of its strategy in 2012. The 
Best practice portal was further developed.
•  Supply and supply reduction interventions: the first joint EMCDDA–Europol strategic 
analysis, the EU drug markets report, was released on 31 January. Work continued to 
develop sub-indicators on drug seizures and drug production facilities, the EMCDDA set 
up its reference group on drug supply, and two Papers were published, one on drug 
squads and one on internal security policies in the EU.
•  New trends and developments: the work of the EWS is both dynamic and increasingly 
challenging, with 81 NPS formally notified in 2013. The Centre prepared and submitted 
to the Council, the EC and the EMA EMCDDA–Europol Joint Reports on four NPS: 
methoxetamine, AH-7921, 25I-NBOMe and MDPV. A risk assessment for 5-IT was 
conducted by the Scientific Committee in April and the agency organised the third 
international multidisciplinary forum on new drugs. The EMCDDA launched a 
trendspotter study on methamphetamine in Europe, which culminated in an expert 
meeting and the conference ‘Testing the waters’, the first international multidisciplinary 
conference on detecting drugs in wastewater, organised with SEWPROF in May.
•  Drug policy analysis: The new EU drugs strategy (2013–20) in the PODs series of online 
reports presents the main features of the strategy endorsed by the JHA Council of the 
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European Union in December 2012. A second ‘Drug policy profile’, on Ireland, was also 
published in 2013.
•  Scientific coordination and content support: to enhance the performance of the 
reporting system, a review of the national reporting package was launched and a 
stronger quality assurance framework was put in place. Transversal work was enhanced 
via three new CUPs, on quality assurance, new trends and the misuse of medicines. The 
treatment CUP also had its mandate renewed.
At the same time, the Centre faced more external demands in 2013 and consequently 
needed to prioritise its tasks and reallocate resources in order to remain responsive to the 
rapid developments in the drugs situation and to meet the needs of its stakeholders. This 
had an impact on the agency’s work programme. The timing of several outputs was 
revised as a result. In July, the Management Board took note of the internal planning 
review carried out by the Centre, in order to reprioritise resources.
Collaboration with key external partners, especially other EU agencies, increased in 2013. 
This included work in the framework of the JHA agencies cluster, and enhanced 
cooperation with Europol, CEPOL and Eurojust, as well as continued collaboration with 
the EMA and ECDC. The EMCDDA stepped up its efforts to strengthen cooperation and 
build synergies with its neighbour agency EMSA, in order to be more efficient and save 
money.
In terms of international cooperation, the Management Board was pleased to learn that 
the EMCDDA had been awarded funding by the EC for a two-year technical assistance 
project in ENP countries, starting in 2014. The Board also gave the Director the mandate 
to negotiate a MoU between the Centre and the National Security Council of the Republic 
of Armenia.
Implementation of the new EMCDDA integrated communication strategy helped enhance 
the Centre’s core communications values, namely relevance, quality, efficiency, 
transparency and consistency.
The agency made significant efforts to further improve its operational efficiency. One 
indicator of these efforts was the outstanding budget execution rate achieved at the end 
of the year.
On the structure of the report:
The 2013 General Report of Activities reflects the agency’s achievements as set out in the 
work programme adopted by the Management Board. The Board appreciates the 
structure of the document, which presents the most important achievements for each of 
the 12 main areas of work, together with a more detailed presentation of the 
implementation of the 2013 work programme, by objectives, activities and expected 
outputs/results (Annex 5). Furthermore, the Management Board welcomes the addition 
of Annex 8 to this activity report, presenting the implementation of follow-up measures to 
the external evaluation of the EMCDDA, carried out in June 2012.
In conclusion, the Management Board finds the report to be a detailed and transparent 
overview of the implementation of the work programme.
Annexes
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I ANNEX 1  EMCDDA Organisational chart
Unit 
Interventions, 
best practice 
and scientific 
partners (IBS) 
Sector Health 
and social 
responses
Unit Supply 
reduction and 
new trends 
(SAT) 
 
Sector Markets, 
crime and supply 
reduction
Sector Action on 
new drugs
Unit 
Prevalence, 
consequences 
and data 
management 
(EPI)
Sector Data 
management and 
statistical 
support
Unit Policy, 
evaluation and 
content 
coordination 
(POL)
Scientific 
division (SDI)
Unit 
Administration 
(ADM) 
 
 
Sector 
Infrastructure 
and logistics
Sector Human 
resources 
management
Sector Financial 
management
Director  
Wolfgang Götz
Data protection 
officer
Director’s office 
(DIR)
Unit Reitox 
and 
international 
cooperation 
(RTX) 
Sector 
International 
cooperation
Unit 
Communication 
(COM) 
 
 
Sector Media 
relations and 
marketing
Unit 
Information 
and 
communication 
technology 
(ICT)
Sector ICT 
project 
management
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Annex 2
I ANNEX 2  Breakdown of EMCDDA staff as of 31 December 2013
Contact agents (CA), Temporary agents (TA), Officials
Categories
Grades Officials
Gender
TA
Gender
Male Female Male Female
AD
15 1 1
14
13 2 2
12 4 3 1 7 4 3
11 1 1 3 2 1
10 7 3 4
9 1 1 1 1
8 1 1 5 3 2
7 10 1 9
6 7 4 3
5
Subtotal AD 7 6 1 43 21 22
AST
11
10 1 1
9 2 1 1
8 1 1 1 1
7 1 1 2 2
6 1 1 3 2 1
5 8 3 5
4 1 1 4 2 2
3 1 1
2
1 1 1
Subtotal AST 5 0 5 22 12 10
TOTAL 12 6 6 65 33 32
Function
group
Gender Total 
EMCDDA
staff
Gender
Male Female Male Female
Contract 
Agents
IV 101 47 54
III 8 4 4 % 46.53 53.47
II 13 1 12
Administrator = AD 
Assistant = AST
I 3 3
Total CA 24 8 16
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United Kingdom
Sweden
Finland
Slovakia
Slovenia
Romania
Portugal
Poland
Austria
Netherlands
Malta
Hungary
Luxembourg
Lithuania
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Cyprus
Italy
France
Spain
Greece
Ireland
Estonia
Germany
Denmark
Czech Republic
Bulgaria
Belgium
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I ANNEX 3  Outputs and products
Annual reporting
European Drug Report 2013: Trends and developments, EMCDDA, Lisbon, May 2013.
A yearly overview of the drug phenomenon in Europe.
Available in 23 languages — all EU official languages (except MT and GA), plus 
Norwegian.
http://www.emcdda.europa.eu/publications/edr/trends-developments/2013
(The home page for the EDR package received 37 833 views in 2013, excluding in-house 
visitors and search engines.)
Statistical bulletin (web-based)
The epidemiological basis on which the European Drug Report is based, with over 300 
tables and 100 graphics collated by the EMCDDA from the information submitted by the 
network of Reitox national focal points.
Available as a website in EN: http://www.emcdda.europa.eu/stats13
Perspectives on drugs (PODs)
Designed-for-the-web interactive analyses providing deeper insights into a selection of 
important issues. 
Synthetic drug production in Europe, EMCDDA, Lisbon, May 2013. 
http://www.emcdda.europa.eu/topics/pods/synthetic-drug-production 
Legal approaches to controlling new psychoactive substances, EMCDDA, Lisbon, May 
2013. 
http://www.emcdda.europa.eu/topics/pods/controlling-new-psychoactive-substances 
Preventing overdose deaths in Europe, EMCDDA, Lisbon, May 2013. 
http://www.emcdda.europa.eu/topics/pods/preventing-overdose-deaths 
Synthetic cannabinoids in Europe, EMCDDA, Lisbon, May 2013. 
http://www.emcdda.europa.eu/topics/pods/synthetic-cannabinoids 
Can mass media campaigns prevent young people from using drugs? EMCDDA, Lisbon, 
May 2013. 
http://www.emcdda.europa.eu/topics/pods/mass-media-campaigns 
Hepatitis C treatment for injecting drug users, EMCDDA, Lisbon, May 2013. 
http://www.emcdda.europa.eu/topics/pods/hepatitis-c-treatment 
The new EU drugs strategy (2013–20), EMCDDA, Lisbon, May 2013. 
http://www.emcdda.europa.eu/topics/pods/eu-drugs-strategy-2013-20 
Characteristics of frequent and high-risk cannabis users, EMCDDA, Lisbon, May 2013. 
http://www.emcdda.europa.eu/topics/pods/frequent-cannabis-users 
Trends in heroin use in Europe — what do treatment demand data tell us?, EMCDDA, 
Lisbon, May 2013. 
http://www.emcdda.europa.eu/topics/pods/trends-in-heroin-use 
Emergency health consequences of cocaine use in Europe, EMCDDA, Lisbon, May 2013. 
http://www.emcdda.europa.eu/topics/pods/cocaine-related-emergencies 
Models for the legal supply of cannabis: recent developments, EMCDDA, Lisbon, May 
2013. 
http://www.emcdda.europa.eu/topics/pods/legal-supply-of-cannabis
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Country overviews
Summaries of the national drug situation, key statistics and a barometer showing the drug 
use prevalence position in each country. In addition to the 30 EMCDDA Member States, 
the following Country overviews are available for IPA beneficiaries: Former Yugoslav 
Republic of Macedonia, Montenegro, Albania, Bosnia and Herzegovina, Kosovo (under 
UNSCR 1244/99), Serbia.
Available online in EN and in national language(s): 
http://www.emcdda.europa.eu/publications/country-overviews
Country overviews (FSU)
Summaries of the national drug situation showing the drug use prevalence position in 
seven former Soviet Union countries: Belarus, Georgia, Moldova, Ukraine, Kazakhstan, 
Kyrgyzstan and Uzbekistan
Available online in EN (for all) and in Russian (for Kazakhstan, Kyrgyzstan and Uzbekistan): 
http://www.emcdda.europa.eu/publications/country-overviews
National reports
Commissioned each year by the EMCDDA and produced by the national focal points of 
the Reitox network, the National reports draw an overall picture of the drugs phenomenon 
at national level in each EU Member State. Published on the EMCDDA website: 
http://www.emcdda.europa.eu/publications/searchresults?action=list&type= 
PUBLICATIONS&SERIES_PUB=w203
Institutional publications
General Report of Activities including annual activity report of the EMCDDA’s authorising 
officer (for 2012), EMCDDA, Lisbon, June 2013.  
http://www.emcdda.europa.eu/publications/general-report-of-activities/2012
2012: a year in review. Highlights from the EMCDDA’s General Report of Activities. 
EMCDDA, Lisbon, June 2013.  
http://www.emcdda.europa.eu/publications/general-report-of-activities/2012-highlights
Annual accounts 2012, EMCDDA, Lisbon, July 2013.  
http://www.emcdda.europa.eu/html.cfm/index214400EN.html
Budget 2013, EMCDDA, Lisbon, January 2013. 
http://www.emcdda.europa.eu/publications/budget-2013
Work programme 2013, EMCDDA, Lisbon, February 2013. 
http://www.emcdda.europa.eu/work-programmes/2013
EMCDDA communication strategy, EMCDDA, Lisbon, June 2013. 
http://www.emcdda.europa.eu/publications/communication-strategy
Strategies
EMCDDA treatment strategy, EMCDDA, Lisbon, April 2013. 
http://www.emcdda.europa.eu/publications/treatment-strategy
Annex 3
81
Outputs linked to the implementation of the Council Decision on new 
psychoactive substances (2005/387/JHA)
EMCDDA–Europol 2012 Annual Report on the implementation of Council Decision 
2005/387/JHA (New drugs in Europe, 2012), EMCDDA, Lisbon, May 2013.
This report presents the results and outlines the key achievements for 2012 on the 
information exchange, risk-assessment and control of new psychoactive substances. 
http://www.emcdda.europa.eu/publications/implementation-reports/2012 (3 554 
downloads in 2013)
EMCDDA–Europol Joint Report on a new psychoactive substance: 5-(2-aminopropyl)
indole, EMCDDA, Lisbon, February 2013. 
http://www.emcdda.europa.eu/publications/joint-reports/5-IT
Toolkits
EMCDDA drug-related infectious diseases monitoring guidance toolkit
Three modules of DRID toolkit on: behavioural indicators for people who inject drugs; 
example questionnaire for bio-behavioural surveys in people who inject drugs; methods of 
bio-behavioural surveys on HIV and viral hepatitis in people who inject drugs – a short 
overview November 2013. 
http://www.emcdda.europa.eu/ activities/drid
EMCDDA Insights
Models of addiction, EMCDDA, Lisbon, June 2013. 
http://www.emcdda.europa.eu/publications/insights/models-addiction
Joint publications
EU drug markets report: a strategic analysis, EMCDDA/Europol, Lisbon, January 2013. 
http://www.emcdda.europa.eu/publications/joint-publications/drug-markets
EMCDDA Papers
Drug squads: units specialised in drug law enforcement in Europe, EMCDDA, Lisbon, 
December 2013. 
http://www.emcdda.europa.eu/publications/emcdda-papers/drug-squads 
Co-morbid substance use and mental disorders in Europe: a review of the data, EMCDDA, 
Lisbon, December 2013. 
http://www.emcdda.europa.eu/publications/emcdda-papers/co-morbidity 
Drug policy advocacy organisations in Europe, EMCDDA, Lisbon, December 2013. 
http://www.emcdda.europa.eu/publications/emcdda-papers/advocacy 
Drug supply reduction and internal security policies in the European Union: an overview, 
EMCDDA, Lisbon, December 2013. 
http://www.emcdda.europa.eu/publications/emcdda-papers/sr-internal-security
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Thematic papers
Drug prevention interventions targeting minority ethnic populations: issues raised by 33 
case studies, EMCDDA, Lisbon, April 2013.
http://www.emcdda.europa.eu/publications/thematic-papers/prevention-minority-
ethnic-populations
North American drug prevention programmes: are they feasible in European cultures and 
contexts?, EMCDDA, Lisbon, June 2013.
http://www.emcdda.europa.eu/publications/thematic-papers/north-american-drug-
prevention-programmes
Drug policy profiles
Drug policy profiles — Ireland, EMCDDA, Lisbon, February 2013. 
http://www.emcdda.europa.eu/publications/drug-policy-profiles/ireland
Brochures
EDR promotional brochure, EMCDDA, Lisbon, June 2013.  
http://www.emcdda.europa.eu/html.cfm/index213171EN.html
Drugnet Europe
Drugnet Europe
The EMCDDA’s quarterly newsletter. Provides regular information on the agency’s 
activities to a broad readership. Four editions in 2013 (81, 82, 83, 84). Available in EN.
http://www.emcdda.europa.eu/publications/drugnet
Ad hoc
European drug prevention quality standards: a quick guide, EMCDDA, Lisbon, October 
2013.
Available in: BS/EN/FR/HR/MK/SL/SQ/SR/TR
http://www.emcdda.europa.eu/publications/adhoc/prevention-standard
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Media products
News releases
12 news releases
No 1: First strategic analysis of the European drug market (25.01.2013) EN
No 2: New drug 4-MA to be placed under control across the EU (07.03.2013) DE/EN/FR/
PT
No 3: EU drugs agency to launch European Drug Report 2013 (30.04.2013) BG/CS/DA/
DE/EL/EN/ES/ET/FI/FR/HU/IT/LT/LV/NL/ PL/PT/RO/SK/SL/SV/NO
No 4: Leading experts to review global developments in detecting illicit drugs in 
wastewater (02.05.2013) EN/PT
No 5: New drugs cause fundamental shift in Europe’s drug market (28.05.2013) DE/EN/
FR/PT
No 6: New European drug report out today: Europe’s drugs problem in ‘state of flux’ 
(28.05.2013) BG/CS/DA/DE/EL/EN/ES/ET/FI/FR/HR/HU/IT/LT/LV/NL/ PL/PT/RO/
SK/SL/SV/NO
No 7: Record levels of treatment, but still a need to invest in new interventions and social 
reintegration (28.05.2013) BG/CS/DA/DE/EL/EN/ES/ET/FI/FR/HR/HU/IT/LT/LV/NL/
PL/PT/RO/SK/SL/SV/NO
No 8: EU drugs and maritime agencies open their doors to the public on inauguration of 
Praça Europa (18.06.2013) EN/PT
No 9: Over 100 specialists from across the globe to review international developments in 
new drugs field (24.06.2013) DE/EN/FR/PT
No 10: New EMCDDA report reveals how a better understanding of the science of 
‘addiction’ can improve our response to drug problems (26.06.2013) EN
No 11: EMCDDA welcomes European Commission call for stronger EU action on new 
drugs (17.09.2013) EN
No 12: 2013 EMCDDA scientific paper award applauds excellence in drug-related 
research (06.11.2013) DE/EN/FR/PT
Fact sheets
13 fact sheets available mostly only in EN
Fact sheet 1: ISCTE–EMCDDA summer school: 1–12 July 2013, Lisbon (15.01.2013)
Fact sheet 2: EMCDDA signs accord with the First Faculty of Medicine of Charles 
University in Prague (22.01.2013)
Fact sheet 3: National drug policy of Ireland explored in new EMCDDA policy profile 
(28.02.2013)
Fact sheet 4: European Parliament LIBE Committee members on fact-finding visit to 
EMCDDA (16.07.2013)
Fact sheet 5: Experts to examine latest scientific research in the field of new drugs 
(12.09.2013)
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Fact sheet 6: New-style EMCDDA expert meetings promote integrated approach to 
monitoring (23.09.2013)
Fact sheet 7: EMCDDA supports national drug observatories via training on contemporary 
approaches to drug monitoring (30.09.2013)
Fact sheet 8: EMCDDA Director opens workshop showcasing Croatia’s national drug 
monitoring system (22.10.2013)
Fact sheet 9: CICAD–OAS Executive Secretary, Ambassador Paul E. Simons, visits 
EMCDDA to discuss cooperation and perspectives for work programme 2014–18 
(06.11.2013)
Fact sheet 10: EMCDDA hosts workshop on evidence sharing to prevent and reduce harm 
related to addiction (25.11.2013)
Fact sheet 11: EMCDDA launches new toolkit for monitoring infectious diseases among 
people who inject drugs (29.11.2013)
Fact sheet 12: EMCDDA launches first four studies in a new series targeting policymakers 
and specialists (12.12.2013)
Fact sheet 13: EU drugs agency announces Scientific Committee line-up for next three 
years (20.12.2013)
News updates
Prevention services for minority ethnic groups explored (18.04.2013)
G8 statement of intent on collecting and sharing of data on new drugs (25.06.2013)
EMCDDA publications recognised by the American Library Association (30.10.2013)
EMCDDA: 20 years (30.10.2013)
Wound botulism among people who inject heroin in Norway – joint ECDC/EMCDDA rapid 
risk assessment (31.10.2013)
Europe takes decisive step forward in monitoring drug supply (15.11.2013)
Videos
EU drug markets report to be launched on 31 January 2013 (10.01.2013)  
http://www.youtube.com/watch?v=RYCZMG3eii4
EU drug markets report: a strategic analysis (31.01.2013) 
http://www.youtube.com/watch?v=ueF-2djqRys
Testing the waters: conference on detecting illicit drugs in wastewater on 6–8 May 2013 
(07.03.2013)  
http://www.youtube.com/watch?v=Gbs6csZODfc
Women and drug use in Europe (07.03.2013) 
http://www.youtube.com/watch?v=Y6XzSzyvSyE
European Drug Report 2013 to be launched on 28 May (30.04.2013) 
http://www.youtube.com/watch?v=o7lVIvFJdGo
Models for the legal supply of cannabis: recent developments (28.05.2013) 
http://www.youtube.com/watch?v=uMclFf56_Zk
Cocaine-related emergencies (28.05.2013) 
http://www.youtube.com/watch?v=VwG_OlcWfUA
Annex 3
85
Hepatitis C treatment among injecting drug users (28.05.2013) 
www.youtube.com/watch?v=DzPhizZAQx0
2013 European drug report (28.05.2013) 
http://www.youtube.com/watch?v=mGbduEIHqm4
Third international multi-disciplinary forum on new drugs (27–28 June) (19.06.2013) 
http://www.youtube.com/watch?v=ev5U6f4voX8
Inauguration of Praça Europa (Lisbon, 20 June 2013) (21.06.2013) 
http://www.youtube.com/watch?v=zznnwSKRbAo
Reitox - the European information network on drugs and drug addiction (28.06.2013) 
http://www.youtube.com/watch?v=dMdOoKOjWPQ
2013 EMCDDA scientific paper award (14.11.2013) 
http://www.youtube.com/watch?v=N8sLeXnhCX0
Social media
Facebook
1871 ‘Likes’ by 31 December 2013
Twitter
270 tweets/retweets in 2013
Online tools and web-based resources
EMCDDA public website
The gateway to drug information in Europe.  
http://www.emcdda.europa.eu
Prevention profiles 
http://www.emcdda.europa.eu/prevention-profiles
Action on new drugs 
http://www.emcdda.europa.eu/activities/action-on-new-drugs
Drug-related research 
http://www.emcdda.europa.eu/themes/research
Best practice portal: A resource for professionals, policymakers and researchers in the 
areas of drug-related prevention, treatment, harm reduction and social reintegration. 
http://www.emcdda.europa.eu/best-practice
ELDD (European Legal Database on Drugs) 
http://www.emcdda.europa.eu/eldd
Treatment profiles 
http://www.emcdda.europa.eu/responses/treatment-overviews
Public expenditure profiles 
http://www.emcdda.europa.eu/countries/public-expenditure
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Scientific articles published in 2013  
(bold indicates EMCDDA staff member(s))
1.  Lloret Irles, D., Espada Sánchez, J. P., Cabrera Perona, V. and Burkhart, G. (2013), 
‘Prevencion Familiar Europa Revision Critica Perspectiva Eddra’, Adicciones 25, pp. 
226–234.
2.  Burkhart, G. (2013), ‘Is environment really a function?’, Prevention Science, 
doi:10.1007/s11121-013-0452-0
3.  Fauzi, F. M., Koutsoukas, A., Cunningham, A., Gallegos, A., Sedefov, R. and Bender, A. 
(2013), ‘Computer-aided (in silico) approaches in the mode-of-action analysis and 
safety assessment of ostarine and 4-methylamphetamine’, Human 
Psychopharmacology: Clinical and Experimental 28, pp. 365–378.
4.  Brandt, S. D., Braithwaite, R. A., Evans-Brown, M. and Kicman, A. T. (2013), 
‘Aminoindane analogues’, in Dargan, P. and Wood, D. (eds.), Novel psychoactive 
substances: classification, pharmacology and toxicology, Academic Press, London, 
pp. 261–283.
5.  Sumnall, H., McVeigh, J. and Evans-Brown, M. (2013), ‘Epidemiology of use of novel 
psychoactive substances’, in Dargan, P. and Wood, D. (eds) Novel psychoactive 
substances: classification, pharmacology and toxicology, Academic Press, London, 
pp. 79–103.
6.  Hope, V. D., McVeigh, J., Marongiu, A., Evans-Brown, M., Smith, J., Kimergard, A., 
Croxford, S., Beynon, C. M., Parry, J. V., Bellis M. A. and Ncube, F. (2013), ‘Prevalence 
of, and risk factors for, HIV, hepatitis B and C infections among men who inject image 
and performance enhancing drugs: a cross-sectional study’, British Medical Journal 
Open 3, doi: 10.1136/bmjopen-2013-003207
7.  Ferri, M. and Bo, A. (2013), ‘EMCDDA best practice promotion in Europe: an Internet 
based dissemination tool’, Adicciones 25, pp. 3–6.
8.  Ferri, M. and Bo, A. ‘Media Campaigns for the prevention of illicit drug use in young 
people’, Cochrane Database of Systematic Reviews, June 5, doi: 10.1002/14651858
9.  Amato, L., Davoli, M., Minozzi, S., Ferroni, E., Ali, R. and Ferri, M. (2013), ‘Methadone at 
tapered doses for the management of opioid withdrawal’, Cochrane Database of 
Systematic Reviews, Issue 2. Art. No.: CD003409.
10.  Minozzi, S., Amato, L., Bellisario, C., Ferri, M. and Davoli, M. (2013), ‘Maintenance 
agonist treatments for opiate-dependent pregnant women’, Cochrane Database of 
Systematic Reviews, 23 December, doi: 10.1002/14651858
11.  Ferri, M., Davoli, M. and D’Amico, R. (2013), ‘Involving patients in setting the research 
agenda in drug addiction’, British Medical Journal 347, 16 July.
12.  Giraudon, I., Lowitz K., Dargan P. I., Wood, D. M. and Dart, R. C. (2013), ‘Prescription 
opioid abuse in the United Kingdom, British Journal of Clinical Pharmacology 76, pp. 
823–824.
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13.  Goosdeel, A. (2013)‚ ‘Für wen tun wir es? Beispiel Europäisches 
Informationsnetzwerk für Drogen und Drogensucht (Reitox)’, 
OrganisationsEntwicklung 4, pp. 96–97.
14.  Griffiths, P., Evans-Brown, M. and Sedefov, R. (2013), ‘Getting up to speed with the 
public health and regulatory challenges posed by new psychoactive substances in 
the information age’, Addiction 108, pp. 1700–1703.
15.  Griffiths, P. and Götz, W. (2013), ‘Foreword’, in Dargan, P. and Wood, D. (eds), Novel 
psychoactive substances: classification, pharmacology and toxicology, Academic 
Press, London, pp. ix–x.
16.  Norden, L., van Veen, M., Guarita, B., Wiessing, L. et al. (2013), ‘Hepatitis C among 
injecting drug users is two times higher in Stockholm, Sweden than in Rotterdam, the 
Netherlands’, Substance Use and Misuse, 48, pp. 1469–1474.
17.  Byford, S., Barrett, B., Metrebian, N., Groshkova, T., Cary, M., Charles, V., Lintzeris, N. 
and Strang, J., (2013), ‘Cost-effectiveness of injectable opioid treatment v. oral 
methadone for chronic heroin addiction’, British Journal of Psychiatry 203, pp. 
341–349.
18.  Groshkova, T., Metrebian, N., Hallam, C. et al. (2013), ’Treatment expectations and 
satisfaction of treatment-refractory opioid-dependent patients in RIOTT, the 
Randomised Injectable Opiate Treatment Trial, the UK’s first supervised injectable 
maintenance clinics’, Drug and Alcohol Review 32, pp. 566–573.
19.  Mravcik, V., Strada, L., Stolfa, J., Bencko, V., Groshkova, T., Reimer, J. and Schulte, B. 
(2013), ‘Factors associated with uptake, adherence, and efficacy of hepatitis C 
treatment in people who inject drugs: a literature review’, Patient Preference and 
Adherence 7, pp. 1067–1075.
20.  Hedrich, D. (2013), ‘Drogenkonsumräume zur Schadensminderung‘, in Grünewald, K. 
and Maisser, G (eds), Kritische Diagnosen: Krankenberichte zum Gesundheitssystem, 
PlanetVerlag, Vienna, pp. 65–66.
21.  Hedrich, D., Kalamara, E., Sfetcu, O., Pharris, A., Noor, A., Wiessing, L., Hope, V. and 
Van de Laar, M. (2013), ‘Human immunodeficiency virus among people who inject 
drugs: is risk increasing in Europe?’, Eurosurveillance 18.
22.  Macarthur, G. J., van Velzen, E., Hedrich, D. et al. (2013), ‘Interventions to prevent HIV 
and Hepatitis C in people who inject drugs: A review of reviews to assess evidence of 
effectiveness’, International Journal of Drug Policy, 20 August 2013, doi: 10.1016/j.
drugpo.2013.07.001
23.  Montanari, L., Baldacchino, A., Pasinetti, M., Thanki, D. and Vicente, J. (2013), 
‘Co-morbidity of substance use and mental disorders: what do we know on the 
prevalence of psychiatric comorbidity in Europe and what are the ways forward?’, 
Mental Health and Substance Use 6, pp. 97–100.
24.  Barrio, G., Montanari, L., Bravo, M.J., Guarita, B., de la Fuente, L., Pulido, J. and 
Vicente, J. (2013), ‘Trends of heroin use and heroin injection epidemics in Europe: 
findings from the EMCDDA treatment demand indicator (TDI)’, Journal of Substance 
Abuse Treatment 45, pp. 19–30.
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25.  Mounteney, J., Zobel, F. and Griffiths, P. (2013), ‘The European drug landscape in 
2013 — highlights from the EMCDDA’s European drug report’, Drugs: Education, 
Prevention and Policy 20, pp. 425—426.
26.  Pirona, A. and Simon, R. (2013), ‘Soziale Reintegration ist notwendig und möglich: 
Evidenz und Ansätze für Drogenkonsumenten in Behandlung‘, Sucht 59, pp. 117–119.
27.  Sedefov, R., Gallegos, A., Mounteney, J. and Kenny, P. (2013), ‘Monitoring novel 
psychoactive substances: a global perspective’, in Dargan, P. and Wood, D. (eds), 
Novel psychoactive substances: classification, pharmacology and toxicology, 
Academic Press, London, pp. 29–54
28.  Thanki, D., Domingo-Salvany, A., Anta, G., Mañe, A., Aleixandre, L., Suelves, J., Beteta, 
B. and Vicente, J. (2013), ‘The choice of screening instrument matters: the case of 
problematic cannabis use screening in Spanish population of adolescents’, ISRN 
Addiction, 2013, Article ID 723131,13
29.  Castiglioni, S., Thomas, K. V., Kasprzyk-Hordern, B., Vandam, L. and Griffiths, P. (2013) 
‘Testing wastewater to detect illicit drugs: state of the art, potential and research 
needs’, Science of the Total Environment (in press).
30.  Mathers, B. M., Degenhardt, L., Bucello, C., Lemon, J., Wiessing, L. and Hickman, M. 
(2013), ‘Mortality among people who inject drugs: a systematic review and meta-
analysis’, Bulletin of the World Health Organization 91, pp. 102–123.
31.  Vickerman, P., Martin, N. M., Roy, A., Beattie, T., Des Jarlais D., Strathdee S., Wiessing, 
L., Hickman, M. and EMCDDA collaborative group (2013), ‘Is the HCV-HIV co-infection 
prevalence amongst injecting drug users a marker for the level of sexual and injection 
related HIV transmission?’, Drug and Alcohol Dependence 132, pp. 172–181.
32.  Hahné, S. J., Veldhuijzen, I. K., Wiessing, L., Lim, T. A., Salminen, M. and Laar, M. 
(2013), ‘Infection with hepatitis B and C virus in Europe: a systematic review of 
prevalence and cost-effectiveness of screening’, BMC Infectious Diseases 13, p. 181.
33.  Sypsa, V., Paraskevis, D., Wiessing, L. et al. (2013), ‘Homelessness and other risk 
factors for HIV infection in the current outbreak among injecting drug users in Athens, 
Greece’, American Journal of Public Health, Epub, doi: 10.2105/AJPH.2013.301656 
(printed Feb. 2014).
34.  Hatzakis, A., van Damme, P., Alcorn, K., Wiessing, L., et al. (2013), ‘The state of 
hepatitis B and C in the Mediterranean and Balkan countries: report from a summit 
conference’, Journal of Viral Hepatitis, 20, Suppl. 2, pp. 1–20.
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I ANNEX 4  Key external events, conferences and meetings, 2013
During 2013, EMCDDA staff participated in 277 external events, conferences and 
technical meetings. Through this participation, they brought their knowledge and 
expertise to international scientific discussions and the various political debates currently 
active in the drugs field. For details of these events, please go to emcdda.europa.eu/
publications/gra/2013/annex4
I ANNEX 5   Implementation of the 2013 work programme by objectives, activities and expected outputs/results
This annex presents in detail the activities contained within the work programme for 2013 
and how they were carried out during the course of the year. It can be found at 
emcdda.europa.eu/publications/gra/2013/annex5
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I ANNEX 6   Members of the EMCDDA’s statutory bodies
Members of the Management Board of the EMCDDA
The Management Board consists of one representative from each Member State, two 
representatives of the European Commission, two independent experts particularly 
knowledgeable in the field of drugs, designated by the European Parliament, and one 
representative from each country which has concluded an agreement with the EMCDDA. 
Non-voting observers, such as from international organisations with which the Centre 
cooperates, may be invited to the Management Board meetings.
Country Member Substitute
Belgium Claude GILLARD Vice-Chairman Philippe DEMOULIN
Bulgaria Tsveta RAYCHEVA
Czech Republic Jindrich VOBOŘIL Lucia KISSOVA
Denmark Katrine RING Erich ERICHSEN
Germany Mechthild DYCKMANS Dirk LESSER
Estonia Anna-Liisa PÄÄSUKENE Veiko KOMMUSAAR
Ireland Susan SCALLY Brendan RYAN
Greece Minerva-Melpomeni MALLIORI Konstantinos GAZGALIDIS
Spain Francisco BABÍN VICH Maria Sofia ARAGÓN SÁNCHEZ
France Laura d’ARRIGO Danièle JOURDAIN MENNINGER
Croatia Željko PETKOVIĆ Sanja MIKULIĆ
Italy Giovanni SERPELLONI Elisabetta SIMEONI
Cyprus Stelios SERGIDES Marios ADONIS
Latvia Dzintars MOZGIS
Lithuania Zenius MARTINKUS Povilas RADZEVIČIUS
Luxembourg Mike SCHWEBAG Alain ORIGER
Hungary Mónika SZÁSZIK Ibolya CSÁKÓ
Malta Richard MUSCAT Marilyn CLARK
Netherlands Wil DE ZWART
Austria Franz PIETSCH Christina KRAL
Poland Piotr JABŁOŃSKI Bogusława BUKOWSKA
Portugal João GOULÃO Chairman Manuel CARDOSO
Romania Sorin OPREA Cătălin NEGOI-NIŢĂ
Slovenia Vesna-Kerstin PETRIČ Jože HREN
Slovakia Zuzana MIKOVA Marcela HORVATHOVA
Finland Elina KOTOVIRTA Kari PAASO
Sweden Ralf LÖFSTEDT
United Kingdom John McCRACKEN Anna RICHARDSON
European Commission Reinhard PRIEBE, Lotte KNUDSEN Jakub BORATYŃSKI, Michael HÜBEL
European Parliament Barbara DÜHRKOP DÜHRKOP, Carla ROSSI Massimo CANU, Katalin FELVINCZI
Norwegian representatives Lilly Sofie OTTESEN Hege Christina BREDESEN
91
Annex 6
Observers
Scientific Committee Marina DAVOLI
Reitox Spokesperson Tim PFEIFFER-GERSCHEL
UNODC Gilberto GERRA
Council of Europe Pompidou Group Thomas KATTAU
WHO Arun NANDA
Members of the Executive Committee
The Management Board is assisted by an Executive Committee. This committee is made 
up of the Chair and Vice-Chair of the Management Board, two other members of the 
Board representing the Member States and appointed by the Board and two 
representatives of the European Commission. The Executive Committee prepares the 
decisions of the Management Board and assists and advises the Director.
João GOULÃO PT (Chairman of the Management Board)
Claude GILLARD
BE (Vice-Chairman of the Management Board 
and Chair of the Budget Committee)
Ms Katrine SCHJØNNING DK
Minerva-Melpomeni MALLIORI GR
2 representatives of the European Commission
Members of the Scientific Committee
The members of this committee are selected for their independence and proven expertise 
in a particular field/speciality, as indicated below.
Issue Name
Legal and criminal justice Krzysztof KRAJEWSKI
Brice DE RUYVER
Risk assessment and basic research Fernando RODRIGUEZ FONSECA
Jean-Pol TASSIN
Political and institutional framework Henri BERGERON
Irmgard EISENBACH-STANGL
Henk GARRETSEN
Epidemiology Marina DAVOLI
Björn HIBELL
Dirk KORF
Matthew HICKMAN
Methodological issues Gerhard BÜHRINGER
John STRANG
Best practice and interventions Michael FARRELL
Richard VELLEMAN
Economic issues Anne-Line BRETTEVILLE JENSEN
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I ANNEX 7   Use of the available resources in 2013
EMCDDA 2013 budget execution by objectives and activities in the 2013 work programme
A. Monitoring and reporting on the drugs problem in Europe (vertical operations)
Objectives and activities of 
EMCDDA 2013 WP
Main organisational 
actors for 
implementation
Assigned HR Initial allocation of budget resources  — non assigned appropriation 
Final allocation of budget resources 
— non assigned appropriation 
Executed budget — non assigned 
appropriation
O TA CA SNE Total HR
Direct cost 
of 
operations
Indirect 
costs of 
operations
Total 
budget 
Direct cost 
of 
operations
Indirect 
costs of 
operations
Total 
budget 
Direct  
cost of 
operations
Indirect 
costs of 
operations
Total 
budget 
execution
Data collection, analysis and quality 
assurance
EPI + IBS + RTX 0.5 2.5 3.5 0 6.5 457 448 641 894 1 099 341 663 823 484 511 1 148 334 661 232.67 484 510.79 1 145 743.47
Monitoring and understanding drug 
use and problems: key indicators 
and epidemiology
EPI 0.5 5 1 0 6.5 565 840 653 090 1 218 930 630 231 424 465 1 054 696 627 771.52 424 464.58 1 052 236.10
Monitoring demand reduction 
responses applied to drug-related 
problems
IBS 2 4.7 0.5 0 7.2 707 995.58 714 860 1 422 856 653 249 465 876 1 119 125 650 699.68 465 875.77 1 116 575.44
Monitoring drug supply and supply 
reduction interventions
SAT 0 2.5 1 1 4.5 381 624 326 867 708 490 510 936 403 759 914 695 508 941.57 403 759.01 912 700.58
Monitoring new trends and 
developments and assessing the 
risks of new substances
SAT 0 3.5 1 0 4.5 420 528 326 867 747 394 552 630 445 170 997 800 550 472.97 445 170.17 995 643.15
Improving Europe's capacity to 
monitor and evaluate policies
POL 0 4 1 0 5 434 596 457 163 891 759 331 461 242 773 574 234 330 167.84 242 773.04 572 940.88
Scientific coordination, research 
and content support
SDI + IBS + POL 1 4.5 0 0 5.5 585 630 549 850 1 135 480 746 099 492 275 1 238 374 743 186.92 492 275.37 1 235 462.29
TOTAL 4 26.7 8 1 39.7 3 553 661.08 3 670 588.88 7 224 249.96 4 088 429 2 958 829 7 047 258 4 072 473.17 2 958 828.73 7 031 301.91
B. Cooperation and collaboration with key external partners (transversal operations)
Objectives and activities of 
EMCDDA 2013 WP
Main organisational 
actors for 
implementation
Assigned HR Initial allocation of budget resources — non assigned appropriation 
Final allocation of budget resources — 
non assigned appropriation 
Executed budget — non assigned 
appropriation
O TA CA SNE Total HR
Direct cost 
of 
operations
Indirect 
costs of 
operations
Total 
budget 
Direct cost 
of 
operations
Indirect 
costs of 
operations
Total 
budget 
Direct cost 
of 
operations
Indirect 
costs of 
operations
Total 
budget 
execution
Cooperation and collaboration with 
key partners
DIR 0 0.5 0 0 0.5 114 472 93 299 207 770 138 647 73 505 212 152 138 106.18 73 504.84 211 611.02
SDI 0 1 0 0 1 132 391 111 765 244 156 245 055 116 469 361 524 244 098.68 116 468.93 360 567.60
Cooperation with key partners: 
candidate and potentiall candidate 
countries and ENP countries and 
other non-EU countries
RTX 0.3 2.3 0 0 2.6 199 890 242 576 442 466 299 162 238 114 537 276 297 994.36 238 114.29 536 108.65
TOTAL 0.3 3.8 0 0 4.1 446 752 447 640 894 392 682 864 428 088 1 110 952 680 199.22 428 088.05 1 108 287.28
Note: Figures are in EUR.
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EMCDDA 2013 budget execution by objectives and activities in the 2013 work programme
A. Monitoring and reporting on the drugs problem in Europe (vertical operations)
Objectives and activities of 
EMCDDA 2013 WP
Main organisational 
actors for 
implementation
Assigned HR Initial allocation of budget resources  — non assigned appropriation 
Final allocation of budget resources 
— non assigned appropriation 
Executed budget — non assigned 
appropriation
O TA CA SNE Total HR
Direct cost 
of 
operations
Indirect 
costs of 
operations
Total 
budget 
Direct cost 
of 
operations
Indirect 
costs of 
operations
Total 
budget 
Direct  
cost of 
operations
Indirect 
costs of 
operations
Total 
budget 
execution
Data collection, analysis and quality 
assurance
EPI + IBS + RTX 0.5 2.5 3.5 0 6.5 457 448 641 894 1 099 341 663 823 484 511 1 148 334 661 232.67 484 510.79 1 145 743.47
Monitoring and understanding drug 
use and problems: key indicators 
and epidemiology
EPI 0.5 5 1 0 6.5 565 840 653 090 1 218 930 630 231 424 465 1 054 696 627 771.52 424 464.58 1 052 236.10
Monitoring demand reduction 
responses applied to drug-related 
problems
IBS 2 4.7 0.5 0 7.2 707 995.58 714 860 1 422 856 653 249 465 876 1 119 125 650 699.68 465 875.77 1 116 575.44
Monitoring drug supply and supply 
reduction interventions
SAT 0 2.5 1 1 4.5 381 624 326 867 708 490 510 936 403 759 914 695 508 941.57 403 759.01 912 700.58
Monitoring new trends and 
developments and assessing the 
risks of new substances
SAT 0 3.5 1 0 4.5 420 528 326 867 747 394 552 630 445 170 997 800 550 472.97 445 170.17 995 643.15
Improving Europe's capacity to 
monitor and evaluate policies
POL 0 4 1 0 5 434 596 457 163 891 759 331 461 242 773 574 234 330 167.84 242 773.04 572 940.88
Scientific coordination, research 
and content support
SDI + IBS + POL 1 4.5 0 0 5.5 585 630 549 850 1 135 480 746 099 492 275 1 238 374 743 186.92 492 275.37 1 235 462.29
TOTAL 4 26.7 8 1 39.7 3 553 661.08 3 670 588.88 7 224 249.96 4 088 429 2 958 829 7 047 258 4 072 473.17 2 958 828.73 7 031 301.91
B. Cooperation and collaboration with key external partners (transversal operations)
Objectives and activities of 
EMCDDA 2013 WP
Main organisational 
actors for 
implementation
Assigned HR Initial allocation of budget resources — non assigned appropriation 
Final allocation of budget resources — 
non assigned appropriation 
Executed budget — non assigned 
appropriation
O TA CA SNE Total HR
Direct cost 
of 
operations
Indirect 
costs of 
operations
Total 
budget 
Direct cost 
of 
operations
Indirect 
costs of 
operations
Total 
budget 
Direct cost 
of 
operations
Indirect 
costs of 
operations
Total 
budget 
execution
Cooperation and collaboration with 
key partners
DIR 0 0.5 0 0 0.5 114 472 93 299 207 770 138 647 73 505 212 152 138 106.18 73 504.84 211 611.02
SDI 0 1 0 0 1 132 391 111 765 244 156 245 055 116 469 361 524 244 098.68 116 468.93 360 567.60
Cooperation with key partners: 
candidate and potentiall candidate 
countries and ENP countries and 
other non-EU countries
RTX 0.3 2.3 0 0 2.6 199 890 242 576 442 466 299 162 238 114 537 276 297 994.36 238 114.29 536 108.65
TOTAL 0.3 3.8 0 0 4.1 446 752 447 640 894 392 682 864 428 088 1 110 952 680 199.22 428 088.05 1 108 287.28
Note: Figures are in EUR. Note: Figures are in EUR.
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C. Supporting the achievement of results (transversal operations)
Objectives and activities of 
EMCDDA 2013 WP
Main organisational 
actors for 
implementation
Assigned HR Initial allocation of budget resources — non assigned appropriation 
Final allocation of budget resources — 
non assigned appropriation 
Executed budget — non assigned 
appropriation
O TA CA SNE Total HR
Direct cost 
of 
operations
Indirect 
costs of 
operations
Total 
budget 
Direct cost 
of 
operations
Indirect 
costs of 
operations
Total 
budget 
Direct cost 
of 
operations
Indirect 
costs of 
operations
Total 
budget 
execution
Communicating the EMCDDA’s 
findings to external audiences 
(including translation)
COM 1 9 2 0 12 1 540 834.03 1 167 509.32 2 708 343.35 1 902 665.21 848 929 2 751 594.42 1 895 239.52 848 929.21 2 744 168.73
Governanance, management and 
networks
Governing bodies + 
Directorate + IBS
3 5.3 2 0 10.3 986 547.19 870 732.45 1 857 279.64 1 098 061.97 700 367 1 798 428.52 1 093 776.47 700 366.56 1 794 143.02
RTX + NFPs’ 
co-financed 
activities
0.7 2.2 1 0 3.9 3 043 177.72 328 410.72 3 371 588.44 3 009 753.53 240 185 3 249 938.38 2 998 007.11 240 184.85 3 238 191.97
TOTAL 4.7 16.5 5 0 26.2 5 570 558.94 2 366 652.49 7 937 211.43 6 010 480.71 1 789 480.62 7 799 961.32 5 987 023.10 1 789 480.62 7 776 503.72
GRAND TOTAL FOR 
OPERATIONS 9 47 13 1 70 9 570 972.35 6 484 881.10 16 055 853.45 10 781 774.44 5 176 397.40 15 958 171.84 10 739 695.50 5 176 397.40 15 916 092.90
D. Support to operations under A, B and C above (overheads)
Objectives and activities of 
EMCDDA 2013 WP
Main organisational 
actors for 
implementation
Assigned HR Initial allocation of budget resources for 
direct cost of supporting activities to be 
distributed to operations
Final allocation of budget resources for 
direct cost of supporting activities to be 
distributed to operations
Executed budget — non assigned 
appropriationO TA CA SNE Total HR
Administration and supporting core 
business
ADM 3 13 7 0 23 3 124 051.76 3 891 399.47 3 891 399.47
Information and communication 
technologies
ICT 0 8 2 0 10 1 134 957.75 1 284 997.93 1 284 997.93
TOTAL 3 21 9 0 33 4 259 009.51 5 176 397.40 5 176 397.40
E. Special projects
Objectives and activities of 
EMCDDA 2013 WP
Main organisational 
actors for 
implementation
Assigned HR Budget — assigned appropriations
O TA CA SNE Total HR Budget allocation — financing received in 2013
Carried-over and carried 
forward from 2012 Total available in 2013 Budget execution
Preparation of IPA Beneficiaries 
Countries for their participation in 
the EMCDDA (IPA4 project — 
second year)
RTX 0 0 2 0 2 350 000.00 171 419.20 521 419.20 412 427.12
Remarks: Note: Figures are in EUR.
Assigned HR = full time equivalent per year; O = officials; TA = temporary agents; CA = contract agents; SNE = seconded national experts
Appropriations for cost/expenditure for operational activities and staff that directly aim at implementing the EMCDDA mission/task/WP
Overheads, i.e. appropriations for cost/expenditure for activities, equipment, infrastructure and staff that indirectly aim at 
implementing the EMCDDA mission/task/WP, as their immediate aim is to support operational activities and staff. These overheads 
are distributed to operational activities in proportion of the human resources assigned for the implementation of these activities.
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technologies
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Assigned HR Budget — assigned appropriations
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Countries for their participation in 
the EMCDDA (IPA4 project — 
second year)
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Economic outturn account (in EUR)
2013 2012 Variation
Funds transferred from the Commission to 
other institutions
0.00 0.00 0.00
Contributions of EFTA countries belonging 
to the EEA
403 235.32 414 660.43 –11 425.11
Recovery of expenses 13 360.02 15 259.72 –1 899.70
Revenues from administrative operations 2 038.01 0.00 2 038.01
Other operating revenue 15 716 351.87 15 709 423.66 6 928.21
TOTAL OPERATING REVENUE 16 134 985.22 16 139 343.81 –4 358.59
Administrative expenses –11 207 146.68 –11 640 333.99 433 187.31
  All staff expenses –8 899 609.85 –9 093 966.77 194 356.92
  Fixed asset−related expenses –243 808.48 –224 482.35 –19 326.13
  Other administrative expenses –2 156 834.03 –2 321 884.87 165 050.84
Operational expenses –4 261 558.26 –4 705 146.05 443 587.79
  Other operational expenses –4 261 558.26 –4 705 146.05 443 587.79
TOTAL OPERATING EXPENSES –15 468 704.94 –16 345 480.04 876 775.10
SURPLUS/DEFICIT FROM OPERATING 
ACTIVITIES 666 280.28 –206 136.23 872 416.51
Financial revenues 0.00 0.00 0.00
Financial expenses –3 266.78 –3 795.19 528.41
Movement in pensions (– expense, + 
revenue)
0.00
Share of net surpluses or deficits of 
associates and joint ventures accounted 
for using the equity method
0.00
SURPLUS/ DEFICIT FROM NON 
OPERATING ACTIVITIES –3 266.78 –3 795.19 528.41
SURPLUS/DEFICIT FROM ORDINARY 
ACTIVITIES 663 013.50 –209 931.42 872 944.92
Minority interest 0.00
Extraordinary gains (+) 0.00
Extraordinary losses (–) 0.00
SURPLUS/DEFICIT FROM 
EXTRAORDINARY ITEMS 0.00 0.00 0.00
ECONOMIC OUTTURN FOR THE YEAR 663 013.50 –209 931.42 872 944.92
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EMCDDA 2013 budget appropriations and execution by nature of expenditure (in EUR)
Title Description EUR
1. Expenditure relating to persons working with the EMCDDA  
  Staff in active employment 9 168 270.22
  Other staff-related expenditure (exchange of officials, etc ) 82 198.96
Total under Title 1 9 250 469.18
2. Expenditure for support activities
  Investment in immovable property, rental of buildings and associated costs 1 632 636.46
  Data processing 483 923.28
  Movable property and associated costs 93 154.77
  Current administrative expenditure + postal charges and telecommunications 123 462.98
  Socio-medical infrastructure 21 014.48
Total under Title 2 2 354 191.97
3. Expenditure for operational activities
  Statutory meetings 154 563.40
  Expenditure on formal and other meetings+representative expenses 379 407.84
  Studies, surveys, consultations 205 016.02
  Publishing and translations 710 326.84
  European Network on Drugs and Drug Addiction Reitox 2 624 558.50
  Missions 237 559.15
Total under Title 3 – Section 1.01 4 311 431.75
Section 1.02 – Total core budget 15 916 092.90
Section 1.03
4. Expenditure relating to other subsidies
  EC financing of specific projects 
  IPA4 financing for implementing pre-accession strategy 350 000.00
5. Other expenses (reserve) 0.00
Total budget 16 266 092.90
Execution of the budget: credit consumption, 2013 (commitments)
Title Description % consumption of  available credits
1. Staff 100.00
2. Expenditure for support activities 99.62
3. Expenditure for operational activities 99.24
4. Expenditure relating to IPA4 79.10
Total consumption of core budget (Titles 1, 2, 3 ) 99.74
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Balance sheet: ASSETS (in EUR)
31.12.2013 31.12.2012 Variation
ASSETS
A. NON CURRENT ASSETS
Intangible assets 109 282.12 165 246.52 −55 964.40
Property, plant and equipment 2 110 997.02 2 219 229.35 −108 232.33
  Land and buildings 1 901 558.72 1 993 048.24 −91 489.52
  Plant and equipment 96 372.72 69 771.02 26 601.70
  Computer hardware 60 909.84 92 570.66 −31 660.82
  Furniture and vehicles 52 155.74 63 839.43 −11 683.69
TOTAL NON CURRENT ASSETS 2 220 279.14 2 384 475.87 −164 196.73
B. CURRENT ASSETS
Inventories 0.00 0.00 0.00
Short-term pre-financing 40 518.80 0.00 40 518.80
  Short-term pre-financing 40 518.80 0.00 40 518.80
  Short-term pre-financing with consolidated EU entities 0.00 0.00 0.00
Short-term receivables 783 536.56 289 047.27 494 489.29
  Current receivables 516 328.33 195 105.69 321 222.64
  Other 266 409.77 92 604.21 173 805.56
   Accrued income 0.00
   Deferred charges 266 409.77 92 604.21 173 805.56
   Accrued income with consolidated EU entities 0.00
   Deferred charges with consolidated EU entities 0.00 0.00
  Short-term receivables with consolidated EU entities 798.46 1 337.37 −538.91
0.00
Cash and cash equivalents 1 146 193.85 691 233.55 454 960.30
TOTAL CURRENT ASSETS 1 970 249.21 980 280.82 989 968.39
TOTAL 4 190 528.35 3 364 756.69 825 771.66
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Balance sheet: LIABILITIES (in EUR)
31.12.2013 31.12.2012 Variation
LIABILITIES
A. Net assets 2 378 565.11 1 715 551.61 663 013.50
Reserves 0.00 0.00 0.00
Accumulated surplus/deficit 1 715 551.61 1 925 483.03 −209 931.42
Economic outturn for the year — profit+/loss– 663 013.50 −209 931.42 872 944.92
TOTAL A 2 378 565.11 1 715 551.61 663 013.50
D. CURRENT LIABILITIES 1 323 063.24 1 649 205.08 −326 141.84
Provisions for risks and charges 12 806.27 146 643.03 −133 836.76
Accounts payable 1 310 256.97 1 502 562.05 −192 305.08
  Current payables 328.00 97 332.34 -97 004.34
  Long-term liabilities falling due within the year 0.00 0.00 0.00
  Sundry payables 0.00 0.00 0.00
  Other 934 195.41 1 136 598.39 −202 402.98
   Accrued charges 927 832.21 1 135 171.70 −207 339.49
   Deferred income 6 363.20 1 426.69 4 936.51
  Accrued charges with consolidated EU entities 0.00
  Deferred income with consolidated EU entities 488 900.00 488 900.00
  Accounts payable with consolidated EU entities 375 733.56 268 631.32 107 102.24
    Pre-financing received from consolidated EU entities 364 406.95 194 430.64 169 976.31
    Other accounts payable against consolidated EU entities 11 326.61 74 200.68 −62 874.07
TOTAL CURRENT LIABILITIES 1 811 963.24 1 649 205.08 162 758.16
TOTAL 4 190 528.35 3 364 756.69 825 771.66
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Budget outturn account for the financial year 2013 (in EUR)
2013 2012
REVENUE
  Balancing Commission subsidy + 15 550 000.00 15 550 920.00
  Other subsidy from Commission (IPA 4) + 350 000.00 350 000.00
  Fee income + 0.00 0.00
  Other income + 435 612.70 437 508.41
TOTAL REVENUE (a) 16 335 612.70 16 338 428.41
EXPENDITURE
  Title I: Staff
  Payments − 9 306 826.89 9 090 681.38
   Appropriations carried over − 36 456.41 47 996.43
  Title II: Administrative expenses
   Payments − 2 149 955.30 2 107 729.51
   Appropriations carried over − 224 628.57 215 217.32
  Title III: Operating expenditure 
   Payments − 4 447 250.36 4 930 444.46
   Appropriations carried over − 240 835.86 158 041.23
TOTAL EXPENDITURE (b) 16 405 953.39 16 550 110.33
OUTTURN FOR THE FINANCIAL YEAR (a-b) –70 340.69 –211 681.92
Cancellation of unused payment appropriations carried over from previous year + 29 845.62 29 154.27
Adjustment for carry-over from the previous year of appropriations available at 
31/12 arising from assigned revenue
+ 198 497.35 301 161.10
Exchange differences for the year (gain +/loss −) +/− –1 679.50 –887.81
Prorata Norway grant 2013 –4 936.51 –74 786.50
BALANCE OF THE OUTTURN ACCOUNT FOR THE FINANCIAL YEAR 151 386.27 42 959.14
Balance year N–1 +/− 42 959.14 103 814.04
Positive balance from year N–1 reimbursed in year N to the Commission − –42 959.14 –103 814.04
Result used for determining amounts in general accounting 151 386.27
Commission subsidy — agency registers accrued revenue and Commission 
accrued expense
15 398 613.73
Pre-financing remaining open to be reimbursed by agency to Commission in year 
N+1
151 386.27
Not included in the budget outturn:
Interest generated by 31/12/13 on the Commission balancing subsidy funds and 
to be reimbursed to the Commission (liability)
+ 10 335.38 6 501.13
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Negotiated procedures launched in 2013
Works Supplies Services TOTAL
Number 
of 
contracts
Volume of 
contracts 
(EUR)
Number 
of 
contracts
Volume of 
contracts 
(EUR)
Number 
of 
contracts
Volume of 
contracts 
(EUR)
Number 
of  
contracts 
%
Volume of 
contracts 
(EUR)
%
EUR >5 000 & <15 000 4 48 102.21 5 46 657.34 83 354 009.31 92 95.8 448 768.86 71.0
EUR >15 000 & <60 000 0 0.00 1 55 000.00 3 128 587.02 4 4.2 183 587.02 29.0
EUR =/> 60 000 0 0.00 0 0.00 0 0.00 0 0.0 0.0 % 0.0
TOTAL 4 48 102.21 6 101 657.34 86 482 596.33 96 100 767 187.55 100
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I ANNEX 8   Monitoring the implementation of the follow-up action plan to the third external evaluation of the EMCDDA
The third external evaluation of the EMCDDA was completed in 2012. The final report 
contains 15 Recommendations, and the Centre prepared an action plan to implement 
them. The description of the contents of the action plan can be found at the following 
address: emcdda.europa.eu/publications/gra/2013/annex8
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I ANNEX 9   List of acronyms and abbreviations
ABAC The EMCDDA’s electronic management and accounting system
ABB activity-based budget
AIEP Association of Foreign Press in Portugal
ALA American Library Association
AOTP Afghan Opiate Trade Project
AVE advertising value equivalent
BCP business continuity plan
BPP Best practice portal
CC candidate countries
CEPOL European Police College
CICAD Inter-American Drug Abuse Control Commission
COPOLAD
Cooperation Programme between Latin America and the European Union 
on Drugs Policies
COSI
Council’s Standing Committee on Operational Cooperation on Internal 
Security
CUP cross-unit project
DECIDE
Developing and evaluating communication strategies for supporting 
informed decisions and practice based on evidence
DG Directorate-General
DRD drug-related deaths indicator
DRID drug-related infectious diseases indicator
EC European Commission
ECDC European Centre for Disease Prevention and Control
EDND European database on new drugs
EDR European Drug Report
EFSQ European Facility Survey Questionnaire
ELDD European Legal Database on Drugs
EMA European Medicines Agency
EMQ European Model Questionnaire
EMSA European Maritime Safety Agency
ENFSI European Network of Forensic Science Institutes
ENP European Neighbourhood Policy
EP European Parliament
EQDP European questionnaire on drug use among prisoners
EQUS project on Minimum Quality Standards in Drug Demand Reduction
ESPAD European School Survey Project on Alcohol and Other Drugs
EU European Union
EUSPR European Society for Prevention Research
EWS Early Warning System
FRA Fundamental Rights Agency
Annex 9
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GPS general population survey
HDG Horizontal Drugs Group
HFP Heads of national focal points
HONLEA Heads of National Drug Law Enforcement Agencies
IALN Inter-Agency Legal Network
IAS Internal Audit Service of the EC
ICS Internal Control Standards
ICT information and communication technology
IPA Instrument for Pre-Accession Assistance
ISCE Instituto Superior de Ciências Educativas
JHA Justice and Home Affairs
KI key indicator
KPI key performance indicator
LIBE Civil Liberties, Justice and Home Affairs Committee (European Parliament)
MASP Multi-Annual Strategic Plans
MDPV methylenedioxypyrovalerone
MEP Member of the European Parliament
MoU Memorandum of Understanding
NFP national focal point
NPS new psychoactive substances
OAP operational action plan
OTS opportunity to see
PDU problem drug use indicator
POD Perspective on drugs
RUN Recovered Users Network
SEWPROF sewage profiling project
SICAD
Serviço de Intervenção nos Comportamentos Aditivos e nas Dependências 
– General Directorate for Intervention on Addictive behaviours and 
Dependencies
TAIEX
Technical Assistance and Information Exchange Instrument managed by 
DG enlargement of the European Commission
TDI treatment demand indicator
UNODC United Nations Office on Drugs and Crime
WHO World Health Organization
4-MA 4-methylamphetamine
5-IT 5-(2-aminopropyl)indole
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About this report
The General Report of Activities is an annual publication 
providing a detailed progress report of the EMCDDA’s 
activities over a 12-month period. Published every 
spring, it catalogues the agency’s achievements in 
each area of its annual work programme. The report 
is a useful information source for all those seeking 
comprehensive information on the agency and its work.
About the EMCDDA
The European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA) is the central source and 
confirmed authority on drug-related issues in Europe. 
For over 20 years, it has been collecting, analysing and 
disseminating scientifically sound information on drugs 
and drug addiction and their consequences, providing 
its audiences with an evidence-based picture of the 
drug phenomenon at European level.
The EMCDDA’s publications are a prime source of 
information for a wide range of audiences including: 
policymakers and their advisors; professionals and 
researchers working in the drugs field; and, more 
broadly, the media and general public. Based in Lisbon, 
the EMCDDA is one of the decentralised agencies of 
the European Union.
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